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ABSTRACT 
KNOWLEDGE-BASED ANALYSIS OF GENOMIC EXPRESSION DATA BY USING 
DIFFERENT MACHINE LEARNING ALGORITHMS FOR THE PURPOSE OF 
DIAGNOSTIC, PROGNOSTIC OR THERAPEUTIC APPLICATION 
by Venkata J. Thodima 
August 2008 
With more and more biological information generated, the most pressing task of 
bioinformatics has become to analyze and interpret various types of data, including 
nucleotide and amino acid sequences, protein structures, gene expression profiling and so 
on. In this dissertation, we apply the data mining techniques of feature generation, feature 
selection, and feature integration with learning algorithms to tackle the problems of 
disease phenotype classification, clinical outcome and patient survival prediction from 
gene expression profiles. 
We analyzed the effect of batch noise in microarray data on the performance of 
classification. Batchmatch, a batch adjusting algorithm based on double scaling method is 
advantageous over Combat, another batch correcting algorithm based on the empirical 
bayes frame work. In order to identify genes associated with disease phenotype 
classification or patient survival prediction from gene expression data, we compared and 
analyzed the performance of five feature selection algorithms. Our observations from 
these studies indicated that Gainratio algorithm performs better and more consistently 
over the other algorithms studied. 
ii 
When it comes to performance metric to choose the best classifiers, MCC gives unbiased 
performance results over accuracy in some endpoints, where class imbalance is more. 
In the aspect of classification algorithms, no single algorithm is absolutely superior to all 
others, though SVM achieved fairly good results in most endpoints. Naive bayes 
algorithm also performed well in some endpoints. Overall, from the total 65 models we 
reported (5 top models for 13 end points) SVM and SMO (a variant of SVM) dominate 
mostly, also the linear kernel performed well over RBF in our binary classifications. 
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CHAPTER I 
INTRODUCTION AND BACKGROUND 
The past two decades witnessed an explosive growth in biological information 
generated by the scientific community. This was caused by major breakthrough advances 
in the field of molecular biology, coupled with advances in genomic technologies. In 
turn, the huge amount of genomic data not only leads to a demand on the computer 
science community to help store, organize and index the data, but also leads to a demand 
for specialized computational tools to view and analyze the data.1 
"Biological science in the 21st century is being transformed from a purely lab-based 
science to an information science as well". 
As a result of this transformation, a new field of science was born, in which 
biology, computer science, and information technology merge to form a single discipline 
called bioinformatics. 
Motivation 
Two decades ago, the main role of bioinformatics was to create and maintain 
databases to store biological information, such as nucleotide and amino acid sequences. 
With more and more data generated, nowadays, the most pressing task of bioinformatics 
1
 http://www.ncbi.nlm.nih.gov/About/primer/bioinformatics.html 
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has moved to analysis and interpretation of various types of data, including nucleotide 
and amino acid sequences, protein domains, protein structures and so on. To meet the 
new requirements arising from the new tasks, researchers in the field of bioinformatics 
are working on the development of new algorithms (mathematical formulas, statistical 
methods, etc.) and software tools which are designed for assessing relationships among 
large data sets, such as methods to locate a gene within a sequence, predict protein 
structure and/or function and understand diseases at gene expression level. 
In recent years, the rapid development of DNA microarray technology has made it 
possible for scientists to measure the expression levels of thousands of genes in a single 
experiment (Schena et al. 1995, Lockhart et al. 1996). Thus, DNA microarray technology 
has found many applications in biomedical research. There are many active research 
applications of this technology in clinical cancer research; it is being used to better 
understand the biological mechanisms underlying oncogenesis (Butte 2002), in cancer 
classification (predictors of good outcome versus poor outcome) (Golub et al. 1999; 
Petricoin et al. 2002; van't Veer et al. 2002), clinical diagnosis (Yeang et al. 2001) and 
in drug discovery studies. One of the main challenging tasks in this clinical cancer 
research is the prediction of outcome, i.e., the potentiality of cancer regression and for 
severe status (metastasis). The need for sensitive and reliable predictors of clinical 
outcomes is crucial for early discovery of cancer patients. Identification of these clinical 
outcomes has direct effect on the choice of optimal therapy for each individual (Perez et 
al. 2004; Pusztai et al. 2005; Simon 2005). 
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Currently, there are two approaches to the computational analysis of gene 
expression data for clinical classification purpose. The two approaches are discrimination 
(supervised learning) and clustering (unsupervised learning). In unsupervised learning, 
the classes are unknown and need to be discovered from the data (Brown et al. 2000). 
This involves estimating the number of classes or clusters by using a clustering algorithm 
such as hierarchical clustering (Eisen et al. 1998; Spellman et al. 1998) or self-organizing 
maps (Tamayo et al. 1999) and assigning objects to these classes. In supervised learning 
(also known as classification, supervised pattern recognition and class prediction), the 
classes are predefined and the goal is to understand the basis for the classification from a 
set of labeled data, also known as the learning set. This learned information is then used 
to build a classifier or model, which will be used to predict the class or label of the future 
unlabeled (blind) data, also known as external validation dataset (Dudoit et al. 2002). 
Recently, significant research effort has been directed to the prediction of clinical 
outcomes for several kinds of cancer on the basis of microarray data, which reported a 
considerable success in this class prediction results (Bair et al. 2004; Beer et al. 2002; 
Bhattacharjee et al. 2001; Khan et al. 2001; Ramaswamy et al. 2003; Rosenwald et al. 
2002; Yeoh et al. 2002). But still there are two problems in this approach, the first is 
when one analysis group's class model or predictor was tested on another group's same 
type of cancer data, the success rate decreased significantly, and the second is 
comparison of the marker gene lists used to predict a model by different groups revealed 
very small overlap (Ein-Dor et al. 2006). 
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The probable explanation for these problems may be due to several variables like 
patient's age, race, sex, etc. and in the case of toxicological data like the amount of dose, 
time, etc. Also, the platform of microarray technology used and the different methods of 
data analysis play a significant role in these discrepancies (Ein-Dor et al. 2006; Michiels 
et al. 2005), which we are studying extensively as one analysis group through 
participating in the Microarray Quality Control Phase II (MAQC-II) project initiated by 
the Federal Drug Administration (FDA). 
Microarray Quality Control (MAQC) Project 
Overview of the Project 
On March 16,2004, the US Food and Drug Administration (FDA) released a 
report on "Innovation/Stagnation: Challenge and Opportunity on the Critical Path to 
New Medical Products", addressing the recent slowdown in innovative medical products 
submitted to the FDA for approval. The report described the urgent need to modernize 
the medical product development process - the Critical Path from bench to bed side, and 
they released the Critical Path Opportunities list that provided a concrete focus for public 
and private efforts in new research development and tools. Among the 76 opportunities in 
fields such as genomics, proteomics and bioinformatics, "Biomarker qualification" and 
"Standards for microarray and proteomics-based identification of biomarkers" were 
cited as the top two opportunities. 
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Microarray technology was identified by the FDA's Critical Path Initiative2 as a 
key tool that holds "vast potential" for personalized medicine through the identification 
of biomarkers. In response to the FDA's CPI, scientists at the FDA's National Center for 
Toxicological Research (NCTR) formally launched the MicroArray Quality Control 
(MAQC) project3 in order to address reliability concerns as well as other performance, 
standards, quality and data analysis issues (Shi et al. 2006). 
Microarray gene expression profiling is being used for a variety of applications, 
two of which are (1) understanding general expression differences in various biological 
populations, classes, states, or conditions, which typically leads to the identification of 
lists of differentially expressed genes (DEGs) that distinguish populations and classes, 
and (2) the development of predictive models or classifiers that accurately predict 
outcomes of an individual based on a gene expression profile. These two types of 
applications have important ramifications and distinctions. In the first, information about 
a population or differences between populations is inferred. In the second, something 
about an individual member of a population is inferred or predicted. Although signatures 
can be used to classify individuals (e.g., assign or associate the individual with a subtype 
of a particular disease), MAQC-II is primarily focused on prediction of health outcomes 
based on microarray measurement of biological samples. These can putatively be used to 
predict response to treatment regimens, patient prognosis, recurrence of disease, survival, 
etc. 
2
 http://www.fda.gov/oc/initiatives/criticalpath/ 
3
 http://www.fda.gov/nctr/science/centers/toxicoinformatics/maqc/ 
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MAQC -1 Findings: Microarrays Are Reproducible and Reliable 
One important goal of the MAQC Phase I was to assess the best performance 
achievable with microarray technology under consistent experimental conditions so that 
future end users will have a benchmark to judge whether the quality of their microarray 
data is comparable. A major challenge to the microarray user is the existence of 
numerous options for analyzing the same data set, this is creating the reproducibility 
problem (Eisenstein 2006). Even though, the reproducibility has seldom been, but in the 
future should be used as a critical criterion to judge the performance of data analysis 
procedures. 
The MAQC-I analyses (Shi et al. 2006) demonstrated that the apparent lack of 
reproducibility reported in previous studies (Marshall 2004; Tan et al. 2003) using 
microarray assays was likely caused, at least in part, by the common practice of ranking 
genes solely by a statistical significance measure, for example, P-values derived from 
simple ^-tests, and selecting differentially expressed genes with a stringent significance 
threshold, a result that is consistent with a previous report. The gene lists in the MAQC 
study were much more concordant when fold change was used as the ranking criterion. In 
addition, widely used statistical methods such as ranking based on false discovery rate 
(FDR) values, t-test using SAM (significance analysis of microarray) did not appear to 
improve inter-laboratory or inter-platform reproducibility compared to fold change 
ranking. Importantly, non-reproducible gene lists could lead to inconsistent biological 
interpretations, for example, in terms of enriched GO (Gene Ontology) terms and 
pathways. Fold change ranking combined with a less stringent P-value cutoff was found 
7 
to yield more reproducible signature gene lists. The effect of various data normalization 
methods on the stability of lists of differentially expressed gene is greatly reduced when 
fold change is used for gene selection. 
M A Q C - 1 : Class Comparison -> What makesthe two populations different? 
Normal Treated 
5> 
Differentially 
Expressed Genes 
(DEGs) 
Betterunderstandingof the biological mechanisms 
M AQC - I I : Class Prediction -> Can the outcome of the new individuals be predicted? 
li Wm 
Normal Cancer 
Diagnosis, treatment outcome, prognosis, personalized 
medicine 
DEGs 
Predictive Models 
(Classifiers) 
Class prediction 
i I 
i 
f Unknown 
Figure 1: Schematic representations of the two major types of applications of microarray 
technology are being addressed in Phase I (top image) and Phase II (bottom image) of the 
MAQC project, i.e., MAQC-I and MAQC-II, respectively. 
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Major findings of the first phase of the MAQC project were published in six 
research papers on the September 8, 2006 issue of Nature Biotechnology (Canales et al. 
2006; Guo et al. 2006; Patterson et al. 2006; Shi et al. 2006; Shippy et al. 2006; Tong et 
al. 2006). 
From MAQC-I to MAQC-II: To investigate the capabilities and limitations of 
microarrays in clinical applications such as disease diagnosis, prognosis, treatment 
outcome and personalized medicine, the MAQC Phase II (MAQC-II) has been launched 
to address technical and scientific issues involved in the development and validation of 
predictive models or classifiers (Figure 1). Multiple datasets were collected and 
distributed for independent analyses to the participating organizations, in which the 
University of Southern Mississippi (USM) group is also actively participating. The 
results will normally be evaluated at three different levels: within a single dataset via 
cross-validation, validation across one or more independent datasets from studies with the 
same (or similar) study objectives, and validation with blinded "prospective" samples. 
Objectives of MAQC-II 
The overall goal of MAQC-II is to comprehensively evaluate different approaches 
for the development and validation of predictive models or classifiers in clinical and 
preclinical (toxicogenomics) applications by applying the same set of approaches to a 
variety of datasets with diverse endpoints on which predictions are being developed. All 
predictions pertain to an individual patient endpoint. 
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Clinical Applications: 
1. Understand the behavior of various prediction rules and gene selection methods 
that may be applied to microarray data sets to produce clinical outcome predictors: (a) 
Examine the influence of the number of variables (probes or probe sets) on prediction 
accuracy and robustness of the prediction result (in cross-validation and in independent 
and "prospective" validation); (b) Examine the influence of prediction rules (algorithms) 
on prediction accuracy and the robustness of prediction results (in cross-validation and in 
independent validation); and (c) Examine robustness of prediction results in the face of 
increasing experimental and artificial noise. 
2. Identify and characterize the sources of variability in multi-gene prediction 
results including (a) Inter- and intra-laboratory variation in prediction results (in replicate 
experiments on the same platform); and (b) Cross-platform performance of prediction 
results (in replicate experiments on different platforms). Only NIEHS (National Institute 
of Environmental Health Sciences) is providing the datasets in two platforms (Affymetrix 
and Agilent) generated using the same experimental setup. 
Preclinical (toxicogenomics) Applications: 
The primary goal is to assess the reliability of models for the prediction of toxicity 
of new chemicals based on the microarray gene expression profiling. The entity to be 
predicted is the toxicological endpoint (e.g., the presence or absence of liver toxicity) for 
a chemical, and usually not for an individual animal. An important note is that in clinical 
applications, the entity to be predicted is usually an outcome of a subject (patient). 
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Design of MAQC-U 
As part of the MAQC - II project, the FDA collected multiple datasets from 
academic and industrial organizations. These datasets were distributed to the participating 
organizations for independent analyses with available methodologies. We received these 
datasets as part of the participating analysis groups after signing the Confidential 
Information Disclosure and Transfer Agreements (CIDTA) from the USM contracts 
office with the corresponding data providers. 
The project is divided into four working groups for better coordination and 
simplification for the participating organizations. 
1. The Clinical Working Group (CWG) focuses on the datasets related to clinical 
applications. The USM has been part of this CWG from the initial stages. 
2. The Toxicogenomics Working Group (TGxWG) focuses on the datasets related to 
toxicogenomics applications. The USM group has been part of this working group 
from the beginning of this group. 
3. The Titrations Working Group (TitrationWG) focuses on the datasets from 
MAQC titration samples (including the MAQC-I Pilot data from 13 titration 
mixtures). The USM group is not a participant in this working group. 
4. The Regulatory Biostatistics Working Group (RBWG) provides recommendations 
to the MAQC-II CWG and TGxWG on the process and criteria for evaluating the 
performance of predictive models and classifiers. This working group evaluates 
and ranks the data analysis plans (DAPs) of the participating analysis groups 
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whether they are within the acceptable statistical framework or not. Before May 
2007, the USM group along with other groups first proposed the Standard 
Operating Procedures (SOPs) for each dataset separately as per the working 
groups teleconference discussions. But after discussions and comments from the 
RBWG on the loopholes in this approach (to have a separate plan for each dataset 
would be biased) in the face-to-face meeting in SAS, Cary, NC in May 2007. The 
statisticians' part of the RBWG unanimously recommended to the participating 
analysis groups to prepare a single comprehensive Data Analysis Plans (DAPs) 
for all the datasets from each group instead of separate plan for each dataset. 
Datasetsfor Clinical and Toxicogenomics: 
Datasets were identified for the purpose of evaluating 
a) The performance of predictive models and classifiers (predictive signatures) and 
b) The performance of different approaches and methodologies for algorithms 
commonly used in the development of predictive models and classifiers. 
Datasetsfor Clinical Working Group: 
Three diseases, namely breast cancer (BR) from the M.D. Anderson Cancer 
Center (MDACC), multiple myeloma (MM) from the University of Arkansas for Medical 
Sciences (UAMS) and neuroblastoma (NB) from the University of Cologne, Germany, 
were considered for more detailed examination for predictive modeling using microarray 
data. I will explain in more detail about these datasets in the Materials and Methods 
chapter. 
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Datasetsfor Toxicogenomics Working Group: 
The goal of the TGxWG is to develop and compare methods for deriving genomic 
signatures from gene expression data that diagnose or predict toxicity of compounds in 
animal models. It should be noted that the individual entities that will be predicted or 
classified are individual chemicals, not individual animals. 
Three datasets are selected to study under this working group. They are Lung 
Tumor in rats from Hamner Institute, Hepatocarcinogenicity in rats from Iconix and 
Overall necrosis score in mouse from NIEHS. These six datasets are explained in detail 
in the Materials part of the chapter III of this dissertation. 
Prediction and Classification Algorithms 
Numerous algorithms have been reported in the literature for developing 
prediction models and classifiers based on microarray gene expression data. The 
Regulatory Biostatistics WG (RBWG) suggested more commonly (and possibly 
appropriate) used methods to be evaluated with the MAQC-II datasets. 
Supervised Learning and Classification Algorithms 
Data mining is to extract implicit, previously unknown and potentially useful 
information from data (Witten et al. 2000). It is a learning process, achieved by building 
computer programs to seek regularities or patterns from data automatically. Machine 
learning provides the technical basis of data mining. One major type of learning we 
address in this dissertation is called classification learning, which is a generalization of 
concept learning. The task of concept learning is to acquire the definition of a general 
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category given a set of positive class and negative class training instances of the category 
(Mitchell et al. 1986). Thus, it infers a Boolean-valued function from the training 
instances. As a more general format of the concept learning, classification learning can 
deal with more than two class instances. 
In practice, the learning process of classification is to find models that can 
separate instances in the different classes using the information provided by training 
instances. Thus, the models generated can be applied to classify a new unknown (blind) 
instance to one of those classes. Stating it in simpler words, given some instances of the 
positive class and some instances of the negative class, can we use them as a basis to 
decide if a new unknown instance is positive or negative (Mitchell et al. 1986)?. This 
kind of learning is a process from general to specific and is supervised because the class 
labels of training instances are clearly known. 
In contrast to supervised learning is unsupervised learning, where there are no 
pre-defined classes or labels for training instances. The main goal of unsupervised 
learning is to decide which instances should be grouped together, or in other words, to 
form the classes. Sometimes, these two kinds of learning methods are used sequentially; 
supervised learning makes use of class information derived from unsupervised learning. 
This two-step strategy has achieved some success in the gene expression data analysis 
field (Alizadeh et al. 2000; Golub et al. 1999), where the unsupervised clustering 
methods were first used to discover classes (for example, subtypes of leukemia) so that 
supervised learning algorithms could be employed to establish classification models and 
assign a clinical outcome or phenotype to a newly coming instance. 
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Gene Expression Data Representation for Classification 
In a typical classification task, data are represented as a table of samples (also 
known as instances). Each sample is described by a fixed number of features (also known 
as attributes, in our case, these were genes) and a label that indicates its class (Hall, 
1998). For example, in studies of clinical outcome classification of cancer samples, gene 
expression data of m genes for n cancer samples is often summarized by an n x (m+1) 
table (X,Y) = (xy, yi), where xy denotes the expression level of gene/ in sample /, and yi 
is the class or label (e.g., erpos in breast cancer) to which sample / belongs (i = 1,2,3,..., n 
and/ = 1,2,..., m). The table (Table 1) below shows a sample dataset with three breast 
cancer samples. 
Sample# 
Samplcl 
S;iin|)li2 
Siiinpli'3 
geneA 
2.004906 
1.445*52 
1.429597 
geneB 
-1.201 IS 
-I.DI2" 
0.567925 
geneC 
0.528131 
I.II6S66 
-0.19037 
geneD 
1.05386 
-0.90285 
3.039217 
geneE 
1.544994 
1.854096 
-0.09884 
Class (label) 
erpos 
crncg 
erpos 
Table 1: This table shows an example of gene expression data. There are three samples, 
each of which is described by 5 genes. The class label in the last column indicates the 
clinical endpoint of the sample. 
Results Evaluation or Error Estimation 
Evaluation is the key to making real progress in supervised classification (Witten 
et al. 2000). To evaluate the performance of classification algorithms, one way is to split 
samples into two sets, training samples and test samples. Training samples are used to 
build a learning model while test samples or external independent dataset (blind dataset) 
are used to evaluate the accuracy of the model. During validation, test samples or blind 
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dataset are supplied to the model, having their class labels "hidden", and then their 
predicted class labels assigned by the model are compared with their corresponding 
original class labels to calculate prediction accuracy. If two labels (actual and predicted) 
of a test sample are same, then the prediction for this sample is counted as a success; 
otherwise, it is an error (Witten et al. 2000). An often used performance evaluation term 
is error rate, which is defined as the proportion of errors made over a whole set of test 
samples. In some cases, we simply use the number of errors to indicate the performance. 
Note that, although the error rate on test samples is often more meaningful to evaluate a 
model, the error rate on the training samples is nevertheless useful to know as well since 
the model is derived from them. 
Predicted 
Neg Pos 
TN 
FN 
FP 
TP 
Figure 2: Confusion matrix for two-class classification problem 
Consider the confusion matrix illustrated in the above figure (Figure 2) of a two-
class ('Pos' and 'Neg') problem. The true positive (TP) and true negative (TN) are 
correct classifications in samples of each class, respectively. A false positive (FP) is 
when a 'Neg' class sample is incorrectly predicted as a 'Pos' class. A false negative (FN) 
is when a 'Pos' class sample is incorrectly predicted as a 'Neg' class. Then each element of 
a confusion matrix shows the number of test samples for which the actual class is the row 
and the predicted class is the column. Thus, the error rate is just the number of false 
positives and false negatives divided by the total number of test samples (i.e., error rate = 
(FP+FN)/(TN+TP+FP+FN)). 
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Error rate is a measurement of overall performance of a classification algorithm (also 
known as a classifier); however, a lower error rate does not necessarily imply better 
performance on a target task. For example, there are 10 samples in class 'Pos' and 90 
samples in class 'Neg'. Suppose, if TP = 5 and TN = 85, then FP = 5, FN = 5 and the 
error rate is 10%. However, only 50% of the samples are correctly classified in class 
'Pos'. So, this is not a perfect evaluation metric in all cases. To more impartially evaluate 
the classification results, some other evaluation metrics are constructed. 
1. True positive rate (TP rate) = TP/(TP+FN), also known as recall or sensitivity, 
measures the proportion of samples in class 'Pos' that are correctly classified as 
class 'Pos'. 
2. True negative rate (TN rate) = TN/(FP+TN), also known as specificity, measures 
the proportion of samples in class 'Neg' that are correctly classified as class 
'Neg'. 
3. False positive rate (FP rate) = FP/(FP+TN) = 1 -specificity. 
4. False negative rate (FN rate) = FN/(TP+FN) = 1-sensitivity. 
5. Another evaluation metric in the classification studies is Matthews Correlation 
Coefficient (MCC). We used this as our priority metric in determining the 
candidate model for each end point as per the RBWG recommendation due to 
more unbalanced classes for each endpoints in our study. 
MCC takes into account true and false positives and negatives and is generally 
regarded as a balanced measure which can be used even if the classes are of very 
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different sizes (significantly unbalanced). It returns a value between -1 and +1. A 
coefficient of+1 represents a perfect prediction, 0 an average random prediction and -1 
the worst possible prediction (Baldi et al. 2000; Matthews 1975). Other measures, such as 
the proportion of correct predictions, are not useful when the two classes are of very 
different sizes. For example, assigning every object to the larger set achieves a high 
proportion of correct predictions, but is not generally a useful classification.4 
(TP*TN)- (FP*F.m 
MCC — 
V'CTP + FP)(TP + FN)(TN + FP} (TN + FN} 
In classification, it is a normal situation that along with a higher TP rate, there 
comes a higher FP rate and same to the TN rate and FN rate. Thus, the receiver operating 
characteristic (ROC) curve was invented to characterize the tradeoff between TP rate and 
FP rate (Zweig et al. 1993). The ROC curve plots TP rate on the vertical axis against FP 
rate on the horizontal axis. With an ROC curve of a classifier, the evaluation metric will 
be the area under the ROC curve. The larger the area under the curve (AUC) (the more 
closely the curve follows the left-hand border and the top border of the ROC space), the 
more accurate the test. Thus, the ROC curve for a perfect classifier has an area of 1. The 
expected curve for a classifier making random predictions will be a line on the 45 degree 
diagonal and its expected area is 0.5. Please refer to Figure 3 (figure slightly modified 
from the courtesy image by Indon, 2007)5 for a sample ROC curve. 
4
 http://en.wikipedia.org/wiki/Matthews_Correlation Coefficient 
5
 http://en.wikipedia.Org/wiki/Image:ROC_space.pnR 
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ROC space 
Figure 3: A sample ROC curve. The dotted line on the 45 degree diagonal is the expected 
curve for a classifier making random predictions. 
Error estimation methods 
If the number of samples for training and testing is limited, a standard way of 
predicting the error rate of a learning technique is to use stratified k-fold cross validation 
(&-fold CV). In A>fold cross validation, first, a full data set is divided randomly into k 
disjoint subsets of approximately equal size, in each of which the class is represented in 
approximately the sample proportions as in the full dataset (Witten et al. 2000). Then the 
above process of training and testing will be repeated k times on the k data subsets. In 
each iteration, (1) one of the subsets is held out in turn, (2) the classifier is trained on the 
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remaining k-l subsets to build classification model, (3) the classification error of this 
iteration is calculated by testing the classification model on the holdout set (Figure 4). 
Finally, the k numbers of errors are added up to yield an overall error estimate. 
Obviously, at the end of cross validation, every sample has been used exactly once for 
testing. 
A widely used selection for A:is 10. Why 10? "Extensive tests on numerous 
different data sets, with different learning techniques, have shown that ten is about the 
right number of folds to get the best estimate of error, and there is also some theoretical 
evidence that backs this up"(Witten et al. 2000). Although 10-fold cross validation has 
become the standard method in practical terms, a single 10-fold cross validation might 
not be enough to get reliable error estimate (Witten et al. 2000). The reason is that, if the 
seed of the random function that is used to divide data into subsets is changed, the cross 
validation with the sample classifier and data set will often produce different results. 
Thus, for a more accurate error estimate, it is suggested to repeat the 10-fold cross 
validation process ten times and average the error rates. This is called 10-fold cross 
validation with ten iterations and naturally, it is a computation-intensive undertaking. 
First we used the 10-fold CV, but based on the recommendations from RBWG in 8th 
face-to-face MAQC meeting, we choose to perform 5-fold CV with ten iterations because 
the Hamner dataset is small and not strong data to use 10-fold with ten iterations. This 
avoids the over fitting problem. 
20 
10-fold Cross Validation 
(9/10) (1/10) 
Performance Evaluation 
Figure 4: A Graphical depiction of 10-fold cross validation 
Instead of running cross validation ten times, another approach for a reliable results is 
called leave-one-out cross validation (LOOCV). LOOCV is simply n-fold cross 
validation, where n is the number of samples in the full data set. In LOOCV, each sample 
in turn is left out and the classifier is trained on all the remaining n-\ samples. 
Classification error for each iteration is judged on the class prediction for the holdout 
sample, success or failure. Different from Mold (k < n) cross validation, LOOCV makes 
use of the greatest possible amount of samples for training in each iteration and involves 
no random shuffling of samples. 
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Classification Algorithms 
There are various ways to find models that separate two or more data classes, i.e. 
to do classification. Models derived from the same sample data can be very different 
from one classification algorithm to another. As a result, different models represent the 
knowledge learned in different formats as well. For example, decision trees represent the 
knowledge in a tree structure; instance-based algorithms, such as nearest neighbor, use 
the instances themselves to represent what is learned; Naive Bayes method represents 
knowledge in the form of probabilistic summaries. In this section, we will describe a 
number of classification algorithms that have been used in this project, including NaiVe 
Bayes, Support Vector Machines (SVM) and Voted Perceptron methods. 
Support Vector Machines (SVM) 
Support vector machines (SVM) is a kind of a blend of linear modeling and 
instance-based learning (Witten et al. 2000), which uses linear models to implement 
nonlinear class boundaries. It originates from research in statistical learning theory 
(Vapnik, 1995). An SVM selects a small number of critical boundary samples from each 
class of training data and builds a linear discriminant function (also called maximum 
margin hyperplane) that separates them as widely as possible. The selected samples that 
are closest to the maximum margin hyperplane are called support vectors. Then the 
f(T~) discriminant function 
for a test sample Tis a linear combination of the support vectors and it is constructed as: 
/ ( r ) = Y oc1.ytCr,..70+& 
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Any of these linear classifiers would be / Maximum margin linear classifier is 
fine, but which one is best? the best classifier 
Figure 5: Graphical representation of Support Vector Machines concept 
where the vectors Xz are the support vectors, } \ are the class labels (which are assumed to 
have been mapped to 1 or -1) of Xu vector Trepresents a test sample. (Xc. T) is the dot 
product of the test sample T with one of the support vectors Xt. «s and b are numeric 
parameters (like weights) to be determined by the learning algorithm. 
In the case that no linear separation is possible, the training data will be mapped 
into a higher-dimensional space H and an optimal hyperplane will be constructed there. 
The mapping is performed by a kernel function K(.,.) which defines an inner product in H 
. Different mappings construct different SVMs (Figure 5). When there is a mapping, the 
discriminant function is given like below which is a representation of a linear SVM. 
f(T)=Y KiytK0CirT) + b 
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An SVM is largely characterized by the choice of its kernel function. There are two types 
of widely used kernel functions; polynomial kernel and Gaussian radial basis function 
(RBF) kernel (Burges, 1998). 
1. A polynomial kernel is if (Z1,X2) = {Kt.X2 + i)d, the value of power d is 
called degree and generally is set as 1, 2 and 3. Particularly, the kernel 
becomes a linear function if d = 1. It is suggested to choose the value of 
degree starting with 1 and increment it until the estimated error ceases to 
improve. However, it has been observed that the degree of a polynomial 
kernel plays a minor role in the final results (Santos et al. 2002) and 
sometimes, linear function performs better than quadratic and cubic 
kernels due to over-fitting of the latter kernels. 
2. An RBF kernel has the form KWi'*z) = e*P( is^t where a is the 
width of the Gaussian. The selection of parameter a can be conducted via 
cross validation or some other manners. When using SVM with RBF 
kernel on gene expression data analysis, Brown group (Brown et al. 2000) 
set a equal to the median of the Euclidean distances from each positive 
samples (sample with class label as 1) to the nearest negative sample 
(sample with class label as -1). 
Besides polynomial kernel and Gaussian RBF kernel, other kernel functions include 
sigmoid kernel (Scholkopf et al. 2002), locality-improved kernel (Zien et al. 2000) and so 
on. 
24 
/(T) = £ «,-yiJfOfijr) + b 
In order to determine parameters a and b in i , the 
construction of the discriminant function finally turns out to be a constrained quadratic 
problem on maximizing the Lagrangian dual objective function (Weston et al. 2001). 
n i n 
under constraints 
n 
«(yt =• 0, «j > 0, (i = 1,2, ...,n) 
where « is the number of samples in training data. However, the quadratic programming 
(QP) problem in the above equation cannot be solved easily via standard techniques since 
it involves a matrix that has a number of elements equal to the square of the number of 
training samples. 
Sequential Minimal Optimization (SMO) 
To efficiently find the solution of the above QP program, Piatt developed the 
sequential minimal optimization (SMO) algorithm (Piatt et al. 1998); one of the fastest 
SVM training methods. Like other SVM training algorithms, SMO breaks the large QP 
problem into a series of smaller possible QP problems. Unlike other algorithms, SMO 
tackles these small QP problems analytically, which avoids using a time-consuming 
numerical QP optimization as an inner loop. The amount of memory required by SMO is 
linear with number of training samples (Piatt et al. 1998). Therefore it is good for large 
I 
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datasets, as in our case, to take advantage of computationally inexpensive aspect. SMO 
has been implemented into Weka, a data mining software package, which we used in this 
study (Witten et al. 2000). 
SVMs have shown to perform well in multiple areas of biological analysis, such 
as detecting remote protein homologies, recognizing translation initiation sites (Liu et al. 
2003; Zeng et al. 2002; Zien et al. 2000), and prediction of molecular bioactivity in drug 
design (Weston et al. 2003). Recently, more and more bioinformaticians employ SVMs 
in their research on evaluating and analyzing microarray expression data (Brown et al. 
2000; Furey et al. 2000; Yeoh et al. 2002). SVMs have many mathematical features that 
make them attractive for gene expression analysis, including their flexibility in choosing 
a similarity function, sparseness of solution when dealing with large data sets, the ability 
to handle large feature spaces, and the ability to identify outliers (Brown et al. 2000). 
In many practical data mining applications, success is measured more subjectively 
in terms of how acceptable the learned description rules, decision trees, or whatever are 
to a human user (Witten et al. 2000). This measurement is especially important to 
biomedical applications such as cancer studies where comprehensive and correct rules are 
crucial to help biologists and doctors understand the diseases (Huiqing, 2004). 
Naive Bayes 
In machine learning, we are interested in determining the best hypothesis h(x) 
from space H, based on the observed training data x. Best hypothesis is almost equal to 
most probable hypothesis, given the data x with any initial knowledge about the prior 
probabilities of the various hypothesis in/7(Jaynes 2003, Richard et al. 2001). 
Bayes theorem provides a way to calculate, 
(i) the probability of a hypothesis based on its prior probability Vx{h(x)) 
(ii) the probabilities of the observing various data given the hypothesis Pr(x|h) 
(iii) the probabilities of the observed data Pr(x) 
We can calculate the posterior probability h(x) given the observed data x, 
Vx(h(x)\x) 
using Bayes theorem. 
. . . . , Fr(%lA6c))Pr(h(x)) 
PKAGO x) = r—rr 
Pr(x) 
Naive Bayes (NB) is a classification model obtained by applying a relatively simple 
method to a training dataset (Mitchell et al. 1986). A NB classifier calculates the 
probability that a given instance (example) belongs to a certain class. It makes the 
simplifying assumption that the features constituting the instance are conditionally 
independent, given the class. 
Given an example X, described by its (xi> •••-• xn) feature vector we are 
looking for a class Cthat maximizes the likelihood: P{X\C) = P(x±,...,xfl\£) 
The (nai've) assumption of conditional independence among the features, given the class, 
allows us to express this conditional probability P(.X\ C) as a product of simpler 
probabilities: P(X\C) = Hf=1 PO^IC). We used the Weka program to train the NB 
classifier. 
Voted Perceptron 
The voted perceptron algorithm proposed by Freund et al. (1999) is based on the 
well known perceptron algorithm of Rosenblatt (1958,1962) and a transformation of 
online learning algorithms to batch learning algorithms developed by Helmbold and 
Warmuth (1995). Moreover, they used the kernel functions proposed by Aizerman, 
Braverman and Rozonoer (1964), to run their algorithm efficiently in very high 
dimensional spaces. This algorithm and its analysis involve little more than combining 
these three known methods. 
Their studies indicate that the use of kernel functions with the perceptron 
algorithm yields a dramatic improvement in performance, both in test accuracy and in 
computation time. In addition, they found that, when training time is limited, the voted-
perceptron algorithm performs better than the traditional perceptron algorithm. 
I discussed about the algorithms which I used for my final classification analysis in this 
project. I have ignored the other algorithms in this discussion which we studied initially 
for preliminary studies like KNN, Random Forest, J48 etc. 
Feature Selection Algorithms 
A well known problem in classification (in general machine learning) is to find 
ways to reduce the dimensionality of the feature space to overcome the risk of over-
fitting especially when we are dealing with gene expression data. Data over-fitting 
happens when the number of features (genes) is large ("curse of dimensionality") and the 
number of training samples is comparatively small ("curse of data set sparsity"). In such 
a situation, a decision function can perform very well on classifying training data, but 
does poorly on test samples. Feature selection is concerned with the issue of 
distinguishing signal from noise in data analysis. 
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Categorization of feature selection algorithms 
Feature selection techniques can be categorized according to a number of criteria 
(Hall et al. 2003). One popular categorization is based on whether the target 
classification algorithm will be used during the process of feature evaluation. A feature 
selection method, that makes an independent assessment only based on general 
characteristics of the data, is named "filter" (Witten et al. 2000); while, on the other hand, 
if a method evaluates features based on accuracy estimates provided by certain 
classification learning algorithm which will ultimately be employed for classification, it 
will be named as "wrapper" (Kohavi et al. 1997, Witten et al. 2000). With wrapper 
methods, the performance of a feature subset is measured in terms of the learning 
algorithm's classification performance using just those features (see Figure 6 below). 
The classification performance is estimated using the normal procedure of cross 
validation, or the bootstrap estimator (Witten et al. 2000). Thus, the entire feature 
selection process is rather computation intensive. For example, if each evaluation 
involves a 10-fold cross validation, the classification procedure will be executed 10 
times. For this reason, wrappers do not scale well to data sets containing many features 
(Hall et al. 2003). Besides, wrappers have to be re-run when switching from one 
classification algorithm to another. 
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Figure 6: Graphical depiction of two feature selection (Filter and Wrapper) approaches. 
In contrast to wrapper methods, filters operate independently of any learning 
algorithm and the features selected can be applied to any learning algorithm at the 
classification stage. Filters have been proven to be much faster than wrappers and hence, 
can be applied to data sets with many features (Hall et al. 2003). Since the biological 
data sets discussed in the later chapters of this dissertation often contain a huge number 
of features (e.g., gene expression profiles), we not only concentrate wrapper but also 
filter methods. 
Another taxonomy of feature selection techniques is to separate algorithms 
evaluating the worth or merit of a subset features from those of individual features. There 
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are some other dimensions to categorize feature selection methods. For example, some 
algorithms can handle regression problem, that is, the class label is numeric rather than a 
discrete valued variable; and some algorithms evaluate and rank features independently 
from class, i.e., unsupervised feature selection (Witten et al. 2000). We will restrict our 
study to the data sets with discrete class label since this is the case of the biological 
problems analyzed in later chapters of this dissertation, though some algorithms 
presented can be applied to numeric class label as well. 
Feature selection algorithms 
There are various ways and algorithms to conduct feature selection. We studied 
five feature selection methods in this project; they are T-test, x statistical measure, gain 
ratio, information gain and Relief-F. 
T-test 
Highly consistent with the well-known ANOVA principle, a basic concept for 
identifying a relevant feature from an irrelevant one is the following: if the values of a 
feature in samples of class 'A' are significantly different from the values of the same 
feature in samples of class '# ' , then the feature is likely to be more relevant than a feature 
that has similar values in iA' and lB\ More specifically, in order for a feature/to be 
relevant, its mean value in iA' should be significantly different from its mean value in 
'fl'(Golubefa/. 1999). 
The classical t-statistic is constructed to test the difference between means of two 
groups of independent samples. So, if samples in different classes are independent, the t-
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statistic can be used to find features that have big difference in mean level between the 
two classes. These features can be then considered to have ability to separate samples 
between different classes (Nguyen et al. 2002). We tested this method in the initial stages 
but did not perform well with over the other methods studied. 
X2 - statistical measure 
X2 measure evaluates features individually by measuring the x2 - statistic with 
respect to the class. Different from the preceding methods, x2 measure can only handle 
features with discrete values, x measure of a feature/with w discrete values is defined 
as, 
i—i L i C . f 
i = l j - 1 *' 
where k is the number of classes, Ati is the number of samples with /th value of/myth 
E-- A--
class. iJ is the expected frequency of lJ and 
By = Ri * Cjfn 
D 
1
 is the number of samples having /th value off, C, is the number of samples in they'th 
class and n is the total number of samples. 
We consider a feature/ to be more relevant than a feature/ (I £j) if y^(fj) > ^(fi). 
Obviously, the worst x value is 0 if the feature has only one value. The 
degree of freedom of the x2 - statistic measure is (w-1) * (k- 1) (Liu et al. 1995). With 
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the degree of freedom known, the critical value for certain significant level can be found 
from the appendix tables provided in most statistics books. 
To apply x2 measure to numeric features, a discretization preprocessing has 
to be taken. The most popular technique in this area is the state-of-art supervised 
discretization algorithm developed by Fayyad and Irani (Fayyad et al. 1993) based on the 
idea of entropy. At the same time, feature selection can be also conducted as a by-product 
of discretization. 
Information gain and Information gain ratio 
Information gain is simply the expected reduction in entropy by partitioning 
the samples according to this feature that it is the amount of information gained by 
looking at the value of this feature. More precisely, the information gain Gain(f,S) of a 
feature/, relatively to a set of samples S, defined as, 
Gam(frS) = Ent(S) - Ent(f,Tf,S) 
where Ent(S) can be calculated from 
k 
Ent(S) = y -p f * logzPt 
and Ent(f, Tf, S) is the class entropy of the feature (for a numeric feature/, 2} is the best 
partition t o / ' s value range under certain criteria, such as MDL principle in 
discretization). Since Ent(S) is a constant once S is given, the information gain and 
entropy measures are equivalent when evaluating the relevance of a feature. In contrast to 
the rule " the smaller the class entropy value, the more important the feature is" that is 
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used in entropy measure, we consider a feature/ to more relevant than a feature// (I ^j) if 
Gaintfj, S)>Gain(f,, S) (Xing et al. 2001, Quinlan 1986). 
However, there is natural bias in the information gain measure - it favors 
features with many values over those with few values. An extreme example is a feature 
having different values in different samples. Although the feature perfectly separates the 
current samples, it is a poor predictor on subsequent samples. One refinement measure 
that has been used successfully is called information gain ratio. The gain ratio measure 
penalizes features that with many values by incorporating amount of split information, 
which is sensitive to how broadly and uniformly the feature splits the data (Mitchell et al. 
1986). 
E f t t ( 5 ) = 2 j ^ j - * logs I£i1 |5 | • "''* |5| 
where Si through Sw are the w subsets of samples resulting from partitioning of S by up-
values discrete or w-value-interval numeric feature/ Then, the gain ratio measures is 
defined in terms of the earlier information gain measure and this split information, as 
follows: 
GainRatio (f, S) = 
Split Information (f, 5) 
Note that split information is actually the entropy of S with respect to the 
values of feature/and it discourages the selection of features with many values (Mitchell 
et al. 1986). For example, if there is total number of n samples in S, the split information 
of a feature/;, which has different values in different samples, is log2n. In contrast, a 
Boolean feature/ that splits the same n samples exactly in half will have split 
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information of 1. If these two features produce the equivalent information gain, then 
clearly feature^ will have a higher gain ratio measure. Generally, a feature/ is 
considered to be more significant than a feature/; (/ ±j) if GainRatio (f, S) > 
GainRatio(fi, S). When using gain ratio measure (or information gain measure) to select 
features, we sort the values of gain ratio (information gain) in the descending order and 
consider those features with highest values. 
ReliefF 
The key idea of ReliefF is to estimate attributes according to how well their 
values distinguish among the instances that are near to each other. For that purpose, given 
an instance, ReliefF searches for its two nearest neighbors: one from the same class 
(called nearest hit) and the other from a different class (called nearest miss). The original 
algorithm of ReliefF (Kira et al. 1992) randomly selects n training instances, where n is 
the user-defined parameter. 
Chapter summary 
In this chapter, I introduced the concept of classification in data mining as well as 
the ways to evaluate the classification performance. I presented in detail some of 
classification algorithms — putting the emphasis on several methods used in the final 
analysis like SVMs, SMO and Naive Bayes. We also used KNN, Random forest, J48 
algorithms to compare and contrast with the above algorithms in our preliminary studies 
which are addressed in later chapter about these studies. 
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Also the basic concepts of feature selection algorithms and the differences 
between filter and wrapper approaches were discussed. Also, the details about the feature 
selection algorithms we studied like t-test, x2 statistic measure, Information gain, 
Gainratio and ReliefF were explained. 
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CHAPTER II 
MATERIALS AND METHODS 
Methods 
One of the important recent breakthroughs in experimental molecular biology is 
microarray technology. This novel technology allows the monitoring of expression levels 
in cells for thousands of genes simultaneously and has been increasingly used in cancer 
research (Alizadeh et al. 2000; Alon et al. 1999; Golub et al. 1999) to understand more of 
the molecular variations among tumors so that a more reliable classification becomes 
possible. 
There are two main types of microarray systems: the cDNA microarrays 
developed in the Brown and Botstein Laboratory at Stanford (DeRisi et al. 1997) and the 
high-density oligonucleotide chips from the Affymetrix company (Lockhart et al. 1996). 
The cDNA microarrays (two-color) are also known as 'spotted' arrays, popularly called 
as 'agilent' prepared from Agilent company (Miller et al. 2002), where the probes are 
mechanically deposited onto modified glass microscope slides using a robotic array 
machine. Oligonucleotide chips are synthesized in silico (e.g., via photolithographic 
synthesis as in Affymetrix GeneChip arrays) are also popularly called as 'single channel' 
arrays. For a more detailed introduction and comparison of the biology and technology of 
the two systems, please refer to Harrington et al. (2000). 
Gene expression data from DNA microarrays are characterized by many 
measured variables (genes or features) on only a few observations (experiments or 
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samples), although both the number of experiments and genes per experiment are 
growing rapidly (Nguyen et al. 2002). The number of genes on a single array is usually in 
the thousands while the number of experiments is only a few tens or hundreds. There are 
two different ways to view data: (1) data points as genes, and (2) data points as samples 
(e.g., patients). In the way (1), the data are presented by expression levels across different 
samples, thus there will be a large number of features and a small number of samples. In 
the way (2), the data is represented by expression levels of different genes, thus the case 
will be a large number of samples with a few attributes. In this dissertation, all the 
discussions and studies on gene expression profiles are based on the format of data 
presentation that is data points as genes or features. 
Microarray experiments raise many statistical questions in many diversified 
research fields, such as image analysis, experimental design, cluster and discriminant 
analysis, and multiple hypothesis testing. The main objectives of most microarray studies 
can be broadly classified into one of the following categories: class comparison, class 
discovery, or class prediction (Miller et al. 2002). 
Class comparison is to establish whether expression profiles differ between 
classes. If they do, which genes are differentially expressed between the classes, i.e. gene 
identification. For example, which genes are useful to distinguish tumor sample from 
non-tumor ones. This is the typical microarray analysis we will perform every day. 
Class discovery is to establish subclusters or structure among specimens or among 
genes. For example, to define previously unrecognized tumor subtypes. 
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Class prediction is to predict a phenotype using information from a gene 
expression profile (Miller et al. 2002). This includes assignment of malignancies into 
known classes (tumor or non-tumor) or tumor samples into already discovered subtypes, 
prediction of patients outcome such as which patients are likely to experience severe drug 
toxicity versus who will have none, or which breast cancer patients will relapse within 
five years of treatment versus who will remain disease free. 
In this dissertation, we will focus on the class comparison and class prediction. 
For these two tasks, supervised analysis methods that use known class information are 
most effective (Miller et al. 2002). In practice, feature selection techniques are used to 
identify discriminatory genes while classification algorithms are employed to build 
models on training samples and predict the phenotype of blind test cases. 
Preprocessing of Expression Data 
Despite optimal techniques to ensure RNA quality, some amount of non-biology-
related variation remains; thus, preprocessing of the microarray data is essential before 
analysis can be initiated. Several critical preprocessing techniques have been developed 
to enhance the validity of microarray analyses. Based on the characteristics of the 
experimental data, the normal preprocessing steps include identification of outlier arrays, 
scale transformation, data normalization, missing value management, batch effect 
correction, replicate handling and so on (Herrero et al. 2003). 
Identification of Outlier Samples 
Array outliers are due to excessive chip-to-chip variation and may be the result of 
improper hybridization errors that create smudges, scratches or cross-hybridization to the 
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microarray (Han et al. 2004). These arrays may have disproportionately high or low 
intensities for individual probe sets due to non-specific or mismatch mRNA binding. 
These changes can sometimes be observed on the DAT file (the image file, not the CEL 
file) of the microarray during visual inspection. It is a better quality control procedure to 
remove the samples from the analysis when their intensities do not match the overall 
tendencies for the same probe sets in the group. 
We used dChip6 analysis to find out the array outliers. It does the probe 
summarization and high-level analysis of gene expression data through model based 
approach by applying Model Based Expression Index (MBEI) algorithm (Li et al. 2001). 
This model is based on a balanced hybridization of all probe sets, in log2 format. When 
the uniformity of hybridization exceeds the model limits, the microarray is identified as 
an outlier. For this algorithm if the standard error for a probe set is more than three times 
larger than the other probe sets on the microarray it is identified as an array outlier. If 
greater than 5% of the probe sets on an individual microarray chips are identified as 
outliers, dChip flags the entire microarray as a potential outlier (Li et al. 2001). MAQC 
asked all the analysis groups to vote each array in the dataset either as outlier (1), 
moderate outlier (0.5) and non-outlier (0). We gave our voting on each array of the 
datasets using this method and also by visualizing the box plot and PCA distribution of 
arrays in the dataset. 
6
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Data Normalization 
The purpose of normalization is to adjust the effects which arise from variations 
in the microarray technology rather than from biological differences between the RNA 
samples or between the printed probes, so that data from different chips can be directly 
compared. No step in the microarray hybridization process can be perfectly controlled. 
The quantity of RNA in a sample varies slightly from chip to chip. Even if the exact same 
sample is used on each of several chips, there will be chip to chip differences in the 
overall distribution of probe intensity values (Bolstad et al. 2003; Irizarry et al. 2006). In 
microarray analysis, the normalization methods vary depending on the technology of the 
arrays we used. In this project, we have total six datasets, among these five datasets are 
Affymetrix single color technology arrays and the Neuroblastoma dataset is Agilent two 
colored customized array. 
We used MAS5 (Microarray Suite Ver. 5) probe-set summarization and 
normalization algorithm from Affymetrix (Affymetrix, 2002) for affymetrix datasets 
(exception to Iconix data, we used Median scale 1000 normalization, because the array is 
customized not the standard array supplied by Affymetrix). There is one specific reason 
for selecting this normalization for this study is that we can accommodate the external or 
blind validation dataset in to the classification system without altering the developed 
model using training dataset. I mean, the normalization step should be independent and 
should not affect the coming external validation dataset in the future. It can be possible 
when the normalization method is done within array instead of across the arrays. MAS5 
algorithm works within array and the other normalization methods like RMA, MBEI 
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(dChip) and PLIER does the normalization between the arrays. So, MAS5 algorithm fits 
well to our study and also MAQC recommendes this normalization for the same reason. 
MAS 5 algorithm 
The MAS5 algorithm uses the TukeyBiweight algorithm, which reweights the 
differences depending on how far the expression values are from the median, and 
discards any differences which are more than five times the median absolute distance 
from the median (Affymetrix, 2002). The MAS 5 algorithm also replaces the MM 
(mismatch) value (MAS4 considers MM values) with a value that is always less than the 
PM (perfect match) value, calculating what is called an ideal mismatch (IM) in this 
situation. Ideal mismatch (IM) intensity value calculated from MM value subtracted from 
PM value (IM is never bigger than PM). 
If MM < PM then IM = MM; 
If MM > PM then IM = PM - correction value; 
Robust mean of probe set values are taken using TukeyBiweight algorithm. In this 
algorithm the mean is calculated to identify center of data. Distance of each data point 
from the mean is calculated (Affymetrix, 2002). This distance determines how each value 
is weighted in the average i.e. outliers far from the median contribute less to the average. 
And the signal is calculated using; 
Signal = TukeyBiweight{log2{PMj - IMj)} 
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We implemented this normalization method on the datasets using affy packages in 
Bioconductor version 2.17 in R 2.5.08 frame work. 
In the case of Neuroblastoma dataset, which is an Agilent platform (two color), 
we used mean scale normalization, a simple scaling normalization method. In the case of 
Iconix dataset, the normalization is median scale 1000 even though it is single color data 
but the platform provider is GE Healthcare, not as usual from Affymetrix. 
Data Transformation 
Missing value transformation: One of the characteristics of the gene expression 
profile is the presence of missing values in the data set. There are diverse reasons that 
cause missing values, including insufficient resolution, image corruption, or simply due 
to dust or scratches on the slide (Troyanskaya et al. 2001). In practice, missing data also 
occur systematically as a result of the robotic methods used to create them. 
Unfortunately, many data analysis algorithms require a complete matrix of gene array 
values as input (Troyanskaya et al. 2001). For example, standard hierarchical clustering 
methods and K-means clustering are not robust to the excess of missing values since the 
calculations in these algorithms are based on a distance matrix. Even with a few missing 
values, they may lose effectiveness. More strictly, some methods like principal 
components analysis (PCA) can not deal with missing values at all. Therefore, methods 
for imputing missing data are needed, not only to minimize the effect of incomplete data 
7
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on further analyses, but also to increase the range of data sets to apply learning 
algorithms. 
There are some general solutions to impute missing values. Here, we list five 
commonly used strategies: (1) filling blanks with zeros; (2) replacing with the gene's 
average expression levels over all experiments; (3) replacing with the median of the 
gene's expression levels over all experiments; (4) singular value decomposition (SVD); 
(5) using weighted KNN imputation method. The KNN based method is to use the k-
nearest neighbours (KNN) to estimate the missing values, where a user is defined 
parameter. 
Both weighted KNN and SVD-based techniques surpass the commonly used 
simple average method (Troyanskaya et al. 2001). This conclusion is very natural since 
the winning methods take advantage of the correlation structure of the data to estimate 
missing expression values. In these two methods, we used KNN based missing value 
imputation method. For this purpose we used ArrayAssist (Stratagene Inc.) package 
installed in the linux computer in the lab. 
Log transformation 
We transformed the normalized raw expression data into log2 transformation for 
better graphical presentation of the data and to continue further analysis with this 
transformed data. 
Quality Control Check 
Filtered genes based on flag values: We filtered the bad quality spots or probe sets 
based on the flag values Present (P) and Marginal (M) calls, we excluded the Absent (A) 
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calls. We also excluded the genes which have either P or M calls in less than half of the 
samples in the dataset. The remaining genes after filtering based on flag values are 
considered for further analysis. 
Quality check with box-plots: We checked the quality of the normalized data 
using the box plot distribution. 
Checking Batch Effect 
Batch effects are observed when the overall intensity of a batch of microarrays 
more closely resembles the batch than the rest of the group, and this tendency may add 
enough noise in the analysis that errors are elevated. Due to the technical limitation that 
all samples cannot be processed simultaneously and must be run in batches, batch effects 
can be a potential confounding factor. This happens when the number of microarrays in a 
study makes it impossible to hybridize each sample to a microarray at the same time, by 
the same technologist, at the same location or with the same lot number of reagents or 
equipment. In our case especially with toxicogenomic datasets, which were designed to 
study the effect of chemical compounds on animal models over the period of years. This 
increases the chance of batch effect in the dataset either by time or the technology used. 
This type of errors ultimately generates false interpretations at the end of the analysis of 
large amount of information. 
We checked for the batch effect in the dataset using unsupervised hierarchical 
clustering between the samples and Principal Component Analysis (PCA). We used two 
types of methods to correct these batch effects. One is Combat, a new function in the 
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bioconductor works based on empirical Bayes framework (Johnson et al. 2007), but it 
requires the class label information to correct the batch. The other method is BatchMatch 
developed by SystemsAnalytics Inc., which works same as the above method but has the 
option to choose to include class label information or not. This is important especially 
when we are doing classification performance with external validation dataset, that does 
not have class label information. We compared both methods on the correction of batch 
in these datasets. 
Dimensionality Reduction /Feature Selection 
The microarray expression data contain thousands of genes; there may be actually a small 
number of underlying variables that account for most of the variation in the data (West et 
al. 2001). For example, a few linear combinations of genes may explain most of the 
response variation. So, dimension reduction is a necessary and crucial part of multivariate 
analysis of high-throughput assay data such as gene expression data. Class prediction 
problem is a multivariate regression problem where the number of variables (genes) far 
exceeds the number of samples. This affects the performance of classification algorithm 
studying to a bottom level and also it is a computationally expensive procedure. One way 
to achieve dimension reduction is to transform the large number of original variables 
(genes) to a new set of variables (gene components) or differentially expressed variables 
(genes), which are uncorrelated and ordered so that the few genes account for most of the 
variation in the data (Figure 7). 
20-40K genes 
Dimension reduction 
Hundreds of genes 
Figure 7: A small schematic depiction of dimensionality reduction of gene expression 
data. 
There are few ways to reduce the dimensionality like Principal Component Analysis 
(PCA), Sliced Inversion Regression (SIR), Partial Least Squares (PLS) and Fold Change 
methods (Li et al. 2007). 
Our approach of dimensionality reduction or feature selection or gene selection is 
in two levels. In the first level we reduced most of unnecessary genes using fold change 
and p-value combination. In the second level we applied feature selection algorithms. 
We combined both fold change and p-value (<0.05) to filter out differentially 
expressed genes. We varied the fold change level from 1.2 to 2 based on the dataset, but 
we fixed the p-value to 0.05. We separated these differentially expressed genes using 
volcano plot, which plots fold change on x-axis and p-value on y-axis, both in log scales. 
So, we can easily separate the genes which fall between certain fold change and p-value 
combination. 
After filtering these differentially expressed genes for all 13 end points in six 
datasets using the corresponding class labels, we checked the box plot distribution for 
those. 
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Feature Selection 
After filtering differentially expressed genes for each end point, we further 
reduced the number of genes or features using information gain, gain ratio, x2 - statistic, 
relief-F and Correlation based feature selection algorithms. These feature selection 
algorithms also ranks genes based on the ranker search algorithm. We discussed about 
feature selection algorithms earlier in this dissertation in feature selections chapter. 
We initially compared and contrasted the above feature selection algorithms to 
find which algorithm performs better to use further in our studies. We ran these with 10-
fold cross validation with 10 iterations with classification algorithms to know which 
feature selection algorithms generate better classification performance. After this, we 
separated the subsets of genes (like 10, 20, 30, 40, 60, 100 genes) based on the ranks in 
each algorithm for further classification studies. 
Classification algorithms 
I explained about the details of the classification algorithms we studied in this 
project in chapter 4 of this dissertation. We used Sequential Minimal Optimization (or 
SMO) with linear kernel by keeping exponential value (E or d) to 1 in polynomial kernel 
of SMO, explained in page number 23. The remaining parameters were kept as default as 
it is in Weka program. In LibSVM, we studied both linear kernel and Radial Basis 
Function (RBF) kernel with c =10 and y = 0.01 and the type of SVM is C-SVC. We also 
studied the voted perceptron and Naive Bayes classification algorithms with default 
options in Weka machine learning framework. The error estimation is performed using 
internal cross validation (CV) with 5-fold CV with 10 iterations. Initially we did 10-fold 
CV with 10 iterations on all datasets, which is a standard and well established. But after 
48 
heated discussion in the MAQC 8 face-to-face meeting in Washington, DC, analysts 
feared to use 10-fold CV on the Hamner dataset, which is small in sample size and weak 
data with strong batch effect, that can introduce the over-fitting in the classification 
performance. So, analysis groups decided to use 5-fold to all datasets instead of 10-fold 
CV. Before this analysis, we tested the implementation of nested cross validation using 
different SVM classification algorithms to avoid introducing over-fitting. After that, work 
flow is designed to fit only stratified cross validation only, due to the difficulty in using 
other classification algorithms in nested cross validation and also stratified CV is 
recommended by the RBWG. 
Error Estimation 
After running these classification algorithms, we tested the internal cross 
validation error estimation using several classification performance metrics as described 
in page number 18 of this dissertation. We reported Matthews Correlation Coefficient 
(MCC), accuracy, sensitivity, specificity, area under ROC curve (AUC) and root mean 
square error (RMSE) performance metric with the standard deviations from the 10 
iterated models for each classification using the confusing matrix generated by 
classification algorithms. Among these we preferred MCC over other performance 
metrics in selecting candidate models for each end point due to heavy imbalanced class 
label datasets we studied. MCC overcomes the bias generated by the imbalanced class 
label datasets by taking of all four elements of the two class confusion matrix into 
consideration. 
Materials 
Datasets used in this project 
We already mentioned very briefly about the six datasets available to study in this 
project in chapter 2 of this dissertation. Here we will go through in detail about the 
datasets and its experimental designs and the clinical endpoints studied in these 
experiments to get a better understanding about the endpoints we are predicting. 
Hamner Lung Tumor dataset 
Subchfante nposnrefollmTisEtbe 
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2(6} 
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NTPfindings 
Figure 8: The experimental design of the Hamner lung tumor dataset from mice 
This is one of the dataset among the three toxicogenomics datasets studied and 
provided by the Hamner Institute (Thomas et al. 2007). The objective of this experiment 
is whether the gene expression at 13 weeks can predict tumor observed at 2 yrs in mice, 
which are exposed to toxic compounds. If the classifier developed from this study is 
valid, then the above hypothesis is true and saves millions of money and time spent for 
National Toxicology Program (NTP), which exposes the animals to toxic compounds 
over 2-3 years. 
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The endpoint we are studying in this experiment is lung tumor formation in two 
year rodent cancer bioassay. For this experiment total 150 female B6C3F1 mice were 
used by exposing to 13 chemicals over a period of 90 days (13 weeks) by Rusty Thomas 
group in the Hamner Institute, NC. Among these chemicals seven were positive for an 
increased incidence of primary alveolar/bronchiolar adenomas or carcinomas and six 
chemicals were negative. Animal treatment was initiated at 5 weeks of age. Mice were 
housed 5 per cage in the same environmental and physical conditions. Animal exposures 
for each chemical were performed via the route and dose recommended by NTP. Refer to 
Thomas et al. 2007for more information about this experimental design. 
Microarray analysis was performed on 3 to 4 animals per treatment group except 
for the corn oil and feed control groups. The microarray platform used for this study is 
Affymetrix mouse 430 version 2. They generated total 70 samples of expression data 
from 22 non-carcinogen (NLT) exposure, 26 carcinogen exposure (LT) and remaining 22 
were treated with controls (Figure 8). These 70 samples were generated in two 
experimental batches (18 in year 2005 and 52 in year 2006). For our analysis purpose, we 
labeled the phenotypic classes as Lung Tumor (LT) and Non-Lung Tumor (NLT) and our 
endpoint code for this class is 'A' with positives to negatives ratio 0.59. We treated the 
control samples also into NLT class as per MAQC recommendation. 
Iconix dataset 
This is another toxicogenomics dataset provided by the Iconix Inc. The 
experimental study is explained in their publication in (Fielden et al. 2007). They studied 
the hepato-carcinogenicity (liver cancer) in rats by exposing them to several chemical 
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compounds. They were exposed to 22 chemical compounds with 2-3 doses per compound 
and 4-5 time points. They treated 3 rats per dose-time combination. The exposure is 
multiple routes depending on the compound. Totally they provided 216 samples of 
expression data on single colored Codelink RU1 platform from GE Healthcare Inc. In 
this, 73 samples are phenotypically classified as liver carcinogenous and 143 samples are 
non-liver carcinogenous and the class is labeled as Class (B) with a positives to negative 
ratio 0.51. The endpoint we are studying is Liver Carcinogen. 
NIEHS dataset 
This is third toxicogenomics dataset in the MAQC datasets provided by the 
National Institute of Environmental Health Sciences (NIEHS), NIH (Lobenhofer et al. 
2006). The experiment is designed by exposing rats with seven acute hepato-toxicants 
and one non-toxic control. The experimental design has four doses for each compound 
and three time points for each compound-dose group and four rats for each dose-time-
compound group with a total of 214 samples. The class is labeled as Class (C) and the 
end point we are studying is the Overall Necrosis Score with positives to negatives ratio 
of 0.58 (79/135). 
MDACC-BR dataset 
This breast cancer (BR) dataset, part of the clinical datasets studied in the MAQC 
was provided by MD Anderson Cancer Center (MDACC) (Hess et al. 2006). They 
studied two clinical end points based on the treatment outcome in this experiment, one is 
pathologic complete response (pCR) and the other one is estrogen receptor status (erpos). 
pCR was defined as no residual invasive cancer in the breast or lymph nodes. Residual in 
52 
situ carcinoma without invasive component was also considered a pCR (Hess et al. 
2006). The gene expression data was provided using Human Affymetrix U133A slides 
from total 130 samples. In this the pCR end point has 0.34 (33/97) positives to negatives 
ratio and erpos end point has 1.6 (80/50) positives to negatives ratio. 
Multiple Myeloma (MM) 
This multiple myeloma (MM) dataset, studied four clinical end points, provided by 
the University of Arkansas Medical Sciences (UAMS) (Shaughnessy et al. 2007a; 
Shaughnessy et al. 2007b). The UAMS provided the 340 samples of gene expression data 
in Affymetrix U133 Plus version 2 platform for the analysis. They studied four clinical 
end points or classes, namely Overall Survival Milestone Outcome (OS_MO), Event-free 
Survival Milestone Outcome (EFS_MO), Clinical Parameter SI (CPS1) and Clinical 
Parameter Rl (CPR1). 
• OS milestone outcome (OSMO) is a coding of a binary clinical outcome (overall 
survival) related to whether the subject survived up to the milestone (24 months): 
1= deceased by 24 months, 0= alive at 24 months. The positive to negatives ratio 
of this end point is 0.48 (112/228). 
• EFS milestone outcome (EFS_MO) is a coding of a binary clinical outcome 
(event-free means disease relapse or progression) related to whether the subject 
was event-free up to the milestone (24 months): l=event occurred < 24 months, 
0=no event in first 24 months. The positives to negatives ratio of this end point is 
1.1 (179/161). 
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• Clinical parameter SI is a coding of binary clinical outcome of parameter SI is 
either positive (1) or negative (0). The data providers did not provide the complete 
description of this parameter based on their confidentiality policy. The positives 
to negatives ratio of this end point is 1.33 (194/146). 
• Clinical parameter Rl is a coding of binary clinical outcome of parameter Rl is 
either positive (1) or negative (0). The positives to negatives ratio of this end 
point is 1.43 (200/140). 
Neuroblastoma (NB) dataset 
This neuroblastoma (NB) clinical dataset is provided by the University of Cologne, 
Germany with four clinical end points to study (Oberthuer et al. 2006). The gene 
expression data they provided is in customized Agilent NB array, which is two color data. 
They provided total 492 expression profiles from 246 NB samples along with dye-flipped 
replicates. The four clinical outcomes in this study are Overall Survival Outcome 
(OSJV10), Event-free Survival Outcome (EFSMO), Newly Established clinical outcome 
Parameter S (NEPS) and Newly Established clinical outcome Parameter R (NEP_R). 
• OS milestone outcome (OS_MO) is a binary coding of overall survival status by 
the milestone (900 days): 0= alive, l=deceased. The positives to negatives ratio in 
this clinical end point is 0.32 (59/187). 
• EFS milestone outcome (EFS_MO) is a coding of binary clinical outcome, event-
free (event-free means disease relapse or progression) survival status with 
consideration of the nature of the event by the milestone (900 days): 0=no event 
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by milestone, l=event by milestone. The positives to negatives ratio in this end 
point is 0.65 (97/145). 
• NEP_S is the newly established clinical outcome parameter S. The positives to 
negatives ratio of this end point is 1.44 (145/101). 
• NEP_R is the newly established clinical outcome parameter R. The positives to 
negatives ratio of this end point is 1.44 (145/101). 
The summarized details about the datasets are given in the Appendix A. 
Chapter summary 
In this chapter, I explained about the methods and materials used in this analysis. I 
explained in detail about the preprocessing steps and quality control measures taken on 
the datasets studied. Also explained about the design of the analysis, the feature selection 
algorithms, classification methods studied and the error estimation methods used. This 
chapter also covered about the datasets studied and the end points (clinical and pre-
clinical outcomes) used in the classification prediction studies. 
55 
CHAPTER III 
RESULTS AND DISCUSSION 
The results of our analysis from preprocessing to classification prediction and 
performance on total 13 clinical and preclinical end points of six different datasets 
studied in this project are explained and discussed in this chapter. 
Outlier identification 
As part of the quality assessment of the arrays of the datasets being studied, we 
did dChip analysis, box plot distribution and PCA (where ever necessary) to identify 
array outliers as described in the methods section of this dissertation. 
For the Hamner dataset, we got the "array summary file" (Table 2) after "Model-
based expression" a pre-processing step from the dChip, and looked for unusual median 
intensity, low P call % and higher array outlier %. 
For each array, array outliers measure the percent of probe sets with expression 
patterns that are inconsistent from the rest of the arrays. In general, dChip gives warnings 
by showing' * ' in the warnings column of the result, when either single or array outlier 
percentages exceed 5% and recommends removal of arrays from further analysis when 
any of these values is 15% or more. None of the chips were flagged based on these 
criteria (Table 2). Finally, I observed the box plot distribution (Figure 9) of these arrays 
using GeneSpring software by selecting RMA pre-processing. 
By carefully observing the two results, we voted GSM 142182 file as single outlier 
in these array files based on its unusual 'Median Intensity' value and low 'P call %' and 
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high '%array outlier'. Also we voted nine other array files as marginal outliers based on 
the above results and rest as non-outliers reported in the voting sheet of MAQC. This 
information is used to do further meta-analysis on the outlier identification methods. 
Number 
55 
7 
68 
30 
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GSM142194 
GSM142174 
GSM142169 
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GSM142175 
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GSM 142181 
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GSM 142153 
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GSM142168 
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111 
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87 
83 
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68.5 
68.3 
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0.251 
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0.228 
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0.133 
0.126 
0.118 
0.109 
0.098 
0.089 
0.089 
0.084 
0.242 
0.211 
0.191 
0.165 
0.185 
0.148 
0.148 
0.18 
0.158 
0.182 
0.134 
0.124 
0.127 
0.14 
0.196 
0.121 
0.178 
0.13 
0.104 
0.141 
0.1 
0.174 
0.141 
0.128 
0.143 
0.109 
0.126 
0.107 
0.088 
0.126 
0.115 
0.12 
Table 2: dChip analysis results of the Hamner dataset which contains 70 array samples. 
The analysis results showed no array is an outlier in the total 70 samples (observe no 
warnings in the warning column in this table). But we voted sample array GSM 142182 as 
an array outlier (shown in orange background above) and marginal outliers (yellow color) 
based on the box plot distribution. 
Figure 9: The figure shown in the next page is the box plot distribution of RMA 
normalized 70 array samples of Hamner dataset to identify array outliers. The red mark 
shown in this figure is voted a array outlier based on dChip analysis and this box plot 
distribution. 
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The outlier identification analysis results for MDACC breast cancer dataset using 
dChip analysis (Table 3) showing significant array outliers. By carefully observing the 
two types of analysis (Figure 10) results as I mentioned above, we voted as array outlier 
for five files in these 176 array files based on its unusual 'Median Intensity' value and 
low 'P call %' and high '%array outlier' (more than 15%). Also we voted 38 other array 
files as marginal outliers and rest as non-outliers. 
Number 
143 
168 
109 
69 
166 
171 
70 
135 
165 
63 
145 
172 
67 
173 
77 
139 
170 
71 
175 
133 
162 
136 
126 
161 
65 
151 
146 
169 
160 
75 
130 
127 
Array 
29539 ABO1833733 35649 
U133A FL151 US129 12 08 05 
28998 AB02091099_34966 
23678 ABO1562100 24635 
U133A FL136 US123 11 14 05 
U133A FL175 US147 01 13 06 2 
23678 AB01562100 26133 
29539 AB01833522 35706 
U133A FL112 US 120 10_13 05 
23678 AB01542220 24643 
29539 ABO1833747 35697 
U133A FL32-US2 05 19 05 
23678 AB01542241 24647 
U133A FL46-314 07 08 05 
23678 AB01562152 24646 
29539 AB01833699 35605 
U133A FL161 US125 01 10 06 
23678 AB01562113 24644 
U133A FL80 US97 09 01 05 
29539 AB01833504 35681 
FL398-PERU53 
29539 AB01833526 35614 
29539 AB01723039 35684 
29539 AB01833935 35648 
23678 AB01542230 24645 
29539 AB01833769 35700 
29539 ABO1833749 35607 
U133A FL15 03 17 05 
29539 ABO1833931 35690 
23678 AB01562130 24648 
29539 AB01723044 35687 
29539 AB01723040 35686 
Median 
Intensity 
62 
60 
93 
48 
211 
149 
48 
80 
113 
76 
64 
105 
65 
90 
75 
97 
90 
66 
95 
107 
92 
90 
79 
86 
73 
89 
100 
101 
82 
65 
97 
92 
% P 
caU 
23.3 
27.3 
32.9 
41.7 
9.1 
19.5 
37.3 
43.8 
26.8 
58.5 
52.8 
19.9 
56.2 
29.8 
46.2 
64.7 
22.1 
55.2 
27.4 
65 
37.2 
63.7 
57.5 
57.2 
55.7 
63.6 
62.9 
19.3 
53.2 
47.6 
55.9 
58.8 
% Array 
outlier 
29.3 
16.654 
16.08 
13.45 
12.22 
12.05 
11.619 
11.152 
10.506 
9.509 
9.492 
9.447 
9.204 
9.034 
9.016 
8.823 
8.729 
8.657 
8.616 
8.594 
8.45 
8.392 
8.257 
7.759 
7.746 
7.629 
7.625 
7.616 
7.387 
7.337 
7.311 
7.198 
% Single 
outlier 
2.378 
1.647 
1.254 
1.023 
2.353 
0.896 
0.957 
1.26 
1.066 
0.551 
1.049 
0.876 
0.511 
0.945 
0.557 
0.25 
0.832 
0.494 
0.824 
0.35 
0.879 
0.359 
0.534 
0.443 
0.447 
0.269 
0.254 
0.69 
0.721 
0.571 
0.582 
0.391 
Warning 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
60 
163 
174 
59 
140 
141 
142 
131 
154 
49 
132 
128 
148 
121 
157 
159 
164 
137 
155 
125 
11 
91 
134 
149 
98 
122 
176 
144 
10 
85 
129 
16 
152 
158 
156 
138 
123 
167 
150 
124 
177 
96 
147 
FL412-PERU55 
U133A FL78 US92 09 01 05 
23678 AB01542151 24650 
29539 AB01833716 35658 
29539 AB01833728 35659 
29539 AB01833732 35677 
29539 AB01723056 35693 
29539 AB01833821 35682 
23678 AB01233000 24649 
29539 ABO1833495 35688 
29539 AB01723041 35689 
29539 AB01833756 35615 
29539 AB01723009 35679 
29539 AB01833840 35610 
29539 AB01833876 35613 
FL454-713 
29539 AB01833535 35695 
29539 AB01833829 35611 
29539 AB01723032 35694 
19893 AB01923090 16992 
24817 AB02262650 26174 
29539 AB01833515 35616 
29539 AB01833758 35698 
24817 AB02263405 26175 
29539 AB01723028 35692 
U133A ROM233 06 04 04 
29539 AB01833741 35650 
19893 AB01913300 16991 
24817 AB02261485 26161 
29539 AB01723043 35685 
19893 AB01983478 17035 
29539 ABO1833780 35612 
29539 AB01833841 35702 
29539 AB01833832 35608 
29539 AB01833542J5683 
29539 AB01723030 35657 
U133A FL137 US134 11 14 05 
29539 AB01833759 35699 
29539 AB01723031 35678 
U133A ROM286 06 04 04 
24817 AB02263399 26158 
29539 AB01833754 35654 
95 
84 
107 
85 
96 
96 
90 
85 
69 
96 
97 
88 
77 
82 
91 
83 
115 
97 
91 
133 
62 
104 
84 
68 
94 
60 
88 
146 
66 
110 
58 
99 
92 
91 
93 
86 
1001 
89 
98 
61 
76 
156 
39.9 
31.1 
56.6 
60.4 
49.8 
61.1 
59.5 
56.4 
56.1 
59.2 
61.6 
62.3 
60.1 
61.8 
59.1 
35.1 
58.1 
64.5 
57.4 
48.6 
56.6 
61.3 
55 
57 
59 
49.2 
58.4 
49 
57.7 
60.9 
47 
60.1 
59.6 
62 
63.8 
60.6 
36.8 
61 
64.1 
53.9 
49.2 
53.6 
7.064 
6.907 
6.844 
6.839 
6.83 
6.444 
6.202 
6.166 
6.067 
6 
5.951 
5.91 
5.803 
5.641 
5.556 
5.533 
5.475 
5.466 
5.439 
5.412 
5.313 
5.287 
5.264 
5.17 
5.026 
4.999 
4.887 
4.802 
4.784 
4.748 
4.604 
4.582 
4.555 
4.542 
4.506 
4.344 
4.313 
4.061 
3.99 
3.904 
3.801 
3.801 
0.771 
0.612 
0.33 
0.423 
0.721 
0.323 
0.488 
0.483 
0.361 
0.42 
0.372 
0.277 
0.495 
0.27 
0.404 
0.545 
0.343 
0.202 
0.501 
0.963 
0.364 
0.216 
0.488 
0.401 
0.384 
0.428 
0.315 
1.028 
0.257 
0.248 
0.488 
0.206 
0.242 
0.235 
0.285 
0.24 
0.537 
0.214 
0.204 
0.309 
0.526 
0.238 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
Table 3: dChip analysis results of the MDACC breast cancer dataset which contains 178 
array samples. The results shows (only 75 arrays results showed due to space constraint) 
57 arrays as an array outliers in the total 178 samples (observe for '*' in warnings 
61 
column). But we voted 5 arrays as an array outlier (shown in orange background above) 
and other 39 as marginal outliers based on the box plot distribution and dChip results. 
Figure 10: The figure shown in the next page is the box plot distribution of RMA 
normalised values for 178 array samples from Iconix. We can observe the most of 
outliers and moderate outliers are in between array numbers 140 to 175. 
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The meta-analysis of the outlier identification methods and its results (Figure 11) 
from the other analysis groups (Appendix B&C) provided by Leming Shi (MAQC 
coordinator) are discussed below. The criteria used for calling the final outlier quality based 
on the consensus score for each array. Consensus score is calculated from, 
Consensus score (%) = 100*(Sum of the votes from n organizations)//? 
MAQC proposed the following rules for assigning an array quality as one of the 
three statuses: 
Status 
Good: 
Marginal: 
Outlier: 
Consensus score (%) 
<33.33%(<l/3 votes) 
>=33.33% and <66.67% (1/3 - 2/3 votes) 
>=66.67% (>=2/3 votes) 
Based the analysis and criteria explained above, MAQC identified a consensus final 
array outliers for all the six datasets used in this project based on the meta-analysis. There are 
no consensus array outliers for Hamner, Iconix, NIEHS datasets. Consensus array outliers are 
found in MDACC breast cancer dataset (19 arrays), MM dataset (5 arrays) and NB dataset (5 
arrays). I shown the array names (Table 4 ) which are excluded for the further analysis, but 
did not show the 38 arrays excluded from MDACC breast cancer dataset. 
Multiple Myeloma dataset 
Consensus array outliers (5) 
P0266-01-B79-U133Plus-2.CEL 
P0748-01-C393-U133Plus-2.CEL 
P0753-01-C413-U133Plus-2.CEL 
P0941-02-C782-U133Plus-2.CEL 
P0984-01-C763-U133Plus-2.CEL 
Neuroblastoma dataset 
Consensus array outliers (5) 
US22502540 251271410122 SOI A02.txt 
US22502540 251271410124 SOI A02.txt 
US22502540 251271410332 SOI A02.txt 
US22502540 251271410531 SOI A02.txt 
US22502540 251271410646 S01 A02.txt 
Table 4: Consensus array outliers which are excluded from the further analysis for MM and 
NB datasets are shown in the above table (not shown the 38 arrays from MDACC-BR 
dataset) 
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Figure 11: Summarized view of the array outlier voting from different analysis groups shown 
in cluster diagram. The left side cluster is for the Hamner dataset and the right side cluster is 
for MDACC breast cancer dataset (data of the matrix shown in the Appendix B&C). 
Preprocessing and Normalization 
We performed the basic preprocessing low level summarization methods for Affymetrix 
datasets (Hamner, NIEHS, MDACC-BR and MM). The normalization we performed on 
these datasets is MAS5 (with a target value 500) to facilitate the incoming external validation 
datasets without any changes to the model developed with training datasets. For Iconix 
dataset, we performed median scale 1000 normalization method and mean scale 
normalization for NB dataset. For NB agilent dataset background correction was applied by 
FG - meanBG calculation. 
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In the next step, we filtered the genes based on the P, M and A absolute flag values 
generated from the MAS5. Also filtered the genes which has low signal values, the threshold 
cut off used based on the dataset we are studying. 
After log2 transformation of signal values, we used KNN- based missing value 
imputation algorithm to predict the missing values. Finally, we performed the quality of the 
arrays with box plot distribution after normalization and compared with before 
normalization. But here, I did not show the distribution results because of the large number 
of samples in the datasets, the quality and appearance of the images are not fine for 
dissertation purpose. 
Batch Effect and Correction 
Batch effect identification and correction is an important step in the quality 
assessment procedure, especially when we are working with large number of samples in the 
datasets. We performed this assessment using correlation heat maps and principal component 
analysis (PC A) and Q-Q plot visualizations of the datasets. We observed strong and 
significant batch effect based on the year of samples generated in Hamner and Iconix 
datasets. There is only slight and insignificant batch effect in the other four datasets studied. 
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2005 2006 
Correlation heat map before batch correction 
Figure 12: Correlation heat map of the Hamner lung tumor dataset with 70 arrays. This heat 
map clearly shows the strong batch effect based on the year of array production. 
We corrected the batch effect using an R function called 'Combat' in the 
bio conductor package. This adjusts the data based on parametric and non-parametric 
empirical Bayes frame work. The complete details about this method are obtained from 
Johnson et al. 2007 paper. We generated the correlation heat maps before (Figure 12) and 
after correcting the batch effect (Figure 13 ). Also we generated principal component analysis 
(PCA) diagrams before (Figure 14a ) and after (Figure 14b) the batch correction. These two 
visualizations clearly show the correction of batch effect present in this dataset using combat 
algorithm. This algorithm also generates Q-Q plots (Figure 15) to check the normality of the 
data. 
2005 2006 
Correlation heat map after batch correction 
Figure 13: Correlation heat map of the Hamner lung tumor dataset with 70 arrays after batch 
correction with combat funtion. This heat map clearly shows the correction of the batch 
effect based on the year of array production. 
"Quantile-quantile plots (also called QQ plots) are used to determine if two data sets come 
from populations with a common distribution. In such a plot, points are formed from the 
quantiles of the data. If the resulting points lie roughly on a line with slope 1, then the 
distributions are the same". (http://mathworld.wolfram.com/Quantile-QuantilePlot.html). 
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(a) 
X-axis: PCA component 1 (25.04% varian... Conditions: 
Y-axis: PCA component 2 (5.949% varian... Colored by: 
Z-axis: PCA component 3 (3.871 % varian... 
user custom Experiment, De... 
Parameteryear 
& 
(b) 
X-axis: PCA component 1 02.43% variance) 
Y-axis: PCA component 2 (7.482% variants) 
2-axis: PCA component 3 (4.101% variance) 
Conditions; user custom Experiment, Default Interpretation 
Colored by ParamatarYear 
Figure 14: Principal component analysis (PCA) of the Hamner lung tumor dataset with 70 
arrays based on the year (samples shown red with year 2005 and yellow with year 2006) (a) 
before batch correction, samples are separated clearly based on the year (b) we cannot 
observe the differentiation based on the year after batch correction. 
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Figure 15: Q-Q plots for the Hamner dataset before correction of batch (top) and after 
correction (bottom). Q-Q plots shows the normality of the dataset, if the quantiles of 
theoretical and samples falls straight on the line (empirical bayes normal line) then the 
dataset is near to normal. 
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Compare with BatchMatch 1.3 
We also compared and contrasted the Batchmatch 1.3 from System Analytics Inc. 
(www.systemsanalystics.com) on the correction of batch effect in these datasets. Batchmatch 
works presently on 'double scaling' algorithm. The results generated from this algorithm 
shows a clear batch effect in both Hamner and Iconix datasets. It generates the visual results 
in correlation heat maps (Figure 16), PCA, sample cluster diagrams and analysis of variance 
(ANOVA). 
Before BatchMate h After Bate hMatcft 
2005 2006 2005 2006 
Figure 16: The above correlation heat maps for Hamner lung tumor dataset shows the same 
results as it was with Combat. The left side image shows before batch correction and right 
side image shows after batch correction. 
In the next page, ANOVA results of Hamner dataset are shown (Figure 17). In Anova 
analysis, two-factor ANOVA (treatment/biological effect and batch effect) with interaction 
term is performed before and after batch effect removal. The total variance and the variance 
percentage of each effect are shown on the pie charts. 
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Before BatchMatch 
Tola! Variance 85219B 
After BatchMatch 
Total Varianee:?22459 
I Biological effect (1 46%) 
I Batch effort (19.43%) 
| Interaction term {1 54%) 
I Error term (77.57%) 
| Biological effect (1.92%) 
I Batch effect (0.18%) 
I Interaction term (2.11%) 
I Error term (95.79%) 
Figure 17: The two-way ANOVA (LT_NLT and Batch label i.e. Year) results for Hamner 
lung tumor dataset shows the adjustment of batch effect. The left side image shows before 
batch correction and right side image shows after batch correction. 
Besides, giving a similar performance in adjusting the batch effect as it was with 
Combat function, the Batchmatch has several advantages over Combat especially in 
predicting classifiers using with or without class label information. Other than this, we have 
the chance of using one, a few, or all batches as reference. Reference batch(s) become 
necessary when the objective of the study is to construct a predictive model using the current 
available dataset to predict the labels of future dataset. 
We performed the same analysis on Iconix liver cancer dataset, which shows strong 
batch effect based on the year 2001 and 2002. The correlation heat maps (Figure 18), PCA 
(Figure 19) and ANOVA (Figure 20) results of this dataset are shown in the next pages. 
Before Baled Match Afiet BatciiMatoli 
200» 
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0.95 
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0.65 
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0.95 
0.85 
0.75 
0.65 
2003 2001 2002 
Figure 18: The correlation heat maps for Iconix liver cancer dataset (216 samples) shows the 
clear batch effect based on the 2001 and 2002 year. The left side image shows before batch 
correction and right side image shows after batch correction. 
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Figure 19: Principal component analysis (PCA) of Iconix liver cancer dataset (216 samples) 
shows the clear batch effect based on the 2001 and 2002 year. The left side image shows 
before batch correction and right side image shows after batch correction. 
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Figure 20: The two-way ANOVA (Class and Batch i.e. Year) results for Iconix liver cancer 
dataset shows the adjustment of batch effect. The left side image shows before batch 
correction and right side image shows after batch correction. 
We also studied the effect of batch in expression data on the performance of class 
prediction. For this analysis, we used SVM and Naive Bayes (NB) classification algorithms 
and the feature selection is based on fold change and p-value and the evaluation by gainratio 
ranking algorithm on the Hamner lung tumor with and without batch adjustment datasets. 
The error estimation was done using 10-f cross validation with 10 iterations and percentage 
of accuracy as performance metric. The features selected in 10, 20, 30, ... 100 subsets based 
on the ranking provided by gainratio algorithm. We observed from these results that the 
batch effect adjusted dataset performed better than uncorrected dataset (Table 5 ). 
Batch effect on classifier performance 
ez 
o 
a 
100 , 
90 ; 
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70 | 
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40 
30 
20 
10 [ 
0 
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SVM_afterbatch; 
NB 
SVM 
10 
77 
79 
65 
70 
20 
82 
86 
77 
75 
30 
83 
89 
80 
79 
40 
80 
84 
74 
69 
50 
79 
77 
76 
71 
60 
81 
79 
62 
64 
70 
77 
78 
62 
66 
80 
62 
70 
59 
61 
90 
64 
69 
61 
63 
100 
57 
63 
55 
59 
Table 5: SVM and Naive Bayes (NB) classification performance based on the % of accuracy 
on the Hamner with and without batch adjusted datasets. The after batch adjusted data 
performed better than the without batch corrected dataset. 
With the above results, we finished the preprocessing of datasets and quality 
assessment. We corrected the batch effect observed in the Hamner lung tumor dataset and 
Iconic liver cancer dataset based on the year they generated the samples. We came to a 
conclusion that Batchmatch and Combat performs similarly, but Batchmatch has several 
advantages over Combat in the application of classification without leaking class label 
information. Also we came to know that batch noise in expression data shows effect on 
classification performance. 
Dimensionality reduction is the next step in our work flow of this analysis after this 
preprocessing and quality check. 
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Dimensionality Reduction 
Feature selection or dimensionality reduction was done by combining fold change 
and p-value using volcano plot, as explained in methods part of this dissertation. The fold 
change used was depending on the number of genes passing the filter for a particular class 
label and dataset, because in some class labels no genes passed the two fold change 
expression. In those cases, we decreased the fold level to 1.1 to get some differentially 
expressed genes (Table 6). 
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Table 6: The differentially expressed genes passed the fold change (>2) and p-value (<0.05) 
using volcano plots for the total 13 end points. The '*' mark indicates the fold level is 
lowered to 1.1. 
We observed the box plot distributions and scatter plots for each endpoint using the 
corresponding filtered differentially expressed genes for that endpoint. Here, I am showing 
the some images for few endpoints for visualizing the differentiation of the class labels. The 
distribution of differentially expressed genes for NIEHS class label, MDACC breast cancer 
pCR and erpos endpoints are shown in Figures 21, 22 and 23. 
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Figure 21:512 differentially expressed genes (FC > 2 and P-value < 0.05) in NIEHS dataset 
with overall necrosis score as class label, (a) Volcano plot and (b) Box plot distribution of 
samples with differentially expressed genes, clearly shows the expression differentiation 
based on its class ' 1 ' (positive) and '0 ' (negative). 
77 
§ 
(a) log2(Fold change) 
2.981 -
1.512 • 
0.585 • 
-0.585 • 
-1.512 • 
-2 .981 • 
a© i© 
* • 
• 
• 
-0.585 -0.259 
(b) 
0.259 0.585 0.995 1.512 
pCFLNeg 
Figure 22: 106 differentially expressed genes (FC>2 and P-value < 0.05) in MDACC breast 
cancer dataset with pCR (pathological complete response) as class label, (a) Volcano plot 
and (b) Scatter plot distribution of samples with differentially expressed genes, clearly shows 
the expression differentiation based on its class pCR-Pos and pCR-Neg. 
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(b) erpos (Non-averaged) 
Figure 23: 197 differentially expressed genes (FC > 2 and P-value < 0.05) in MDACC breast 
cancer dataset with erpos (estrogen receptor positive) as class label, (a) Volcano plot and (b) 
Box plot distribution of samples with differentially expressed genes, clearly shows the 
expression differentiation based on its erpos class ' 1' (positive) and '0' (negative). 
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After dimensionality reduction of the expression data, our next step to follow is 
feature evaluation or feature selection methods, which detect and rank the best classifier 
genes for that particular endpoint. 
Feature Selection /Evaluation 
Feature selection or evaluation is very crucial step in developing better classifiers. So, we 
studied five feature selection or evaluation algorithms, namely gainratio (Table 7a), chi-
square statistic (Table 7b), information gain (Table 7c), relief (Table 7d) and SVM (Table 7e) 
on Hamner lung tumor dataset and MDACC breast cancer dataset by applying SMO, 
LibSVM, Multi Layer Perceptron (MLP), NB, Random Forest (RF) and J48 classification 
algorithms with 10-f CV with 10 iterations to find the best algorithm. 
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Table 7: The five feature selection algorithms classification performance with six different 
classification algorithms, (a) Gain ratio (b) Chi-Square statistic (c) Information gain (d) 
relief-F and (e) SVM feature selection algorithms. Gain ratio algorithm performs better and 
consistent with all classification algorithms. 
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The feature selection algorithms also run with 10-f CV with 10 iterations. The 
performance of the internal CV error estimation was based on the percentage of accuracy. 
The graphs (Table 7 a, b, c, d, e) shown above from grain ratio performs better and consistent 
with all the classification algorithms we studied. Also, an information gain algorithm 
performs similar to gain ratio to some extent because of the similarity in their algorithms. 
From the above analysis on the Hamner dataset and also from breast cancer dataset, we 
decided to choose gain ratio algorithm as our choice of feature selection algorithm for further 
analysis in predicting classifiers. 
After, deciding gain ratio as our feature selection algorithm, we implemented this 
feature selection algorithm within the cross validation of the classifier, also called as 
stratified cross validation. 
Classification /Error estimation 
Initially, we performed several approaches and workflow designs to develop classifier 
models on the Hamner lung tumor dataset to overcome batch effect and other over-fitting 
bias. I will present those initial approaches and its brief results on the Hamner dataset before 
going to our final generic work flow for all the six datasets. 
05+06 approach 
In the first approach, we studied three classes Lung Tumor, Non-Lung Tumor and 
Control (LT+NLT_Ctr) by combing year 2005 and 2006 (05+06) lung tumor data of Hamner 
with total 70 samples. In this three class prediction, the better performance came from 
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multilayer perceptron (MLP) with around 75 percentage of accuracy (Tables 8, 9). But the 
MLP algorithm is computationally expensive; it takes days, to even small matrix like Hamner 
dataset. It is not recommendable to do with big datasets like 200 - 300 samples. 
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Table 8: Classification performance of three class (LT, NLT and Ctr) prediction using 
Hamner lung tumor dataset with 05+06 approach. 
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Table 9: Classification performance of only two class (LT and NLT+Ctr) prediction using 
Hamner dataset with 05+06 approach. 
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Table 10: Classification performance of chemical compound based (multi class) prediction 
using Hamner dataset with 05+06 approach. 
Later,we studied the same using only two classes (LT and NLT), here we combined 
NLT and control samples and treated both of them as NLT class. In this case, the 
classification performance drastically increased with LibSVM with around 90 % of accuracy. 
This indicates that LibSVM or other SVMs perform better with two class dataset than three 
class or multi class datasets. 
We also studied, the prediction of chemical compounds exposed to mice to study lung 
carcinogenicity using the Hamner dataset. There are totall6 chemical compounds studied, 
among these, 7 lung carcinogenic, 6 non-carcinogenic chemicals and 3 control chemicals. 
Also the 70 samples are highly imbalanced between 2005 and 2006; 2005 has only total 18 
samples (6-Ctr, 6-NLT and 6-LT) and 2006 has 52 samples in total (16-Ctr, 16-NLT and 20-
LT). The above results (Table 10 ) shows very poor classification performance based on the 
chemical studied due to small number of samples and highly imbalanced classes. Because of 
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this poor performance, MAQC excluded the multiclass prediction from the studies and 
confined to only two class prediction for each endpoint. 
Nested cross-validation with (05+06) and (06 ->05) approaches 
In the next appraoch, we implimented nested crossvalidation to avoid over-fitting bias with 
normal crossvalidation only on the test dataset samples using GEMS (Statnikov et al. 2005) 
tool. Nested crossvalidation (Figure 24) is embeding an another layer of crossvalidation 
within the training dataset of external crossvalidation for parameter tuning. There will two 
cross validations in this, the external cross validation for error estimation of the classifier and 
the internal cross validation for parameter tuning within the traning set of external CV. 
? Use tuned 
• parameters 
' Use tuned 
parameters 
Use tuned 
parameters 
Outer crttu-waJfikriiMi 
mrafaafffotikwttte 
•..sap-* 3 
Inner crou-validatta n 
Tune parameter J 
^^^J Trainings set 
4sr Test set 
Figure 24: The schematic depiction of nested crossvalidation, with inner crossvalidation 
within the outer crossvalidation (Image courtesy from MCRestimate package in Bioconductor) 
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In the GEMS, we have the chance to use only several variants of SVM algorithms but 
several feature selection methods. It automatically builds the models and selects the best 
model by parameter (C and y) tuning. We also tested our feature selection, gainratio method 
with this approach, performs better than the inbuilt features. The results are shown in the 
table (Table 11) below. 
Classifiers 
Classifier 1 
Classifier 2 
Classifier 3 
Classifier 4 
Classifier 5 
Cross-
validation 
design 
10-fCV 
(outer) 
9-fCV 
(inner) 
10-fCV 
(outer) 
9-fCV 
(inner) 
10-fCV 
(outer) 
9-fCV 
(inner) 
LOOCV 
(outer) 
10-fCV 
(inner) 
10-fCV 
(outer) 
9-fCV 
(inner) 
Type of MC-
SVM 
Classification 
(RBF with grid 
search) 
OVR, OVO 
DAGSVM, 
WW 
CS 
OVR,CS 
OVO, OVR, 
DAGSVM, CS 
Feature 
selection 
KW, S2N 
OVR, 
S2N OVO, 
BW 
KW, S2N 
OVR, 
S2N OVO, 
BW 
KW, S2N 
OVR, 
S2N OVO, 
BW 
KW, S2N 
OVR, 
S2N OVO, 
BW 
Gain Ratio 
fromWEKA 
Complexity 
96011 
models 
192011 
models 
144011 
models 
739271 
models 
192011 
models 
Best Model 
Characteristics 
69.8% accuracy 
OVR 
C=10,7=0.1s 
30 genes by Anova 
(KW) 
70.5% accuracy 
WW 
C=10,7=0.01 
30 genes by Anova 
(KW) 
71.3% accuracy 
CS 
C=l, 7=0.1 
30 genes by Anova 
(KW) 
67% accuracy 
OVR 
C=10,7=0.01 
30 genes by Anova 
(KW) 
72.8% accuracy 
OVO 
C=10. 7=0.1 
Table 11: The classification performance and the best classifiers using nested cross validation 
in GEMS. We approached 05+06 combined data for binary class prediction. 
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We also studied using 06 -> 05 approach, in this, we used 2006 dataset to train and 
test with 2005 dataset. This results are shown below in the table (Tablel2). 
Classifiers 
Classifier 1 
Classifier 2 
Classifier 3 
Cross-
validation 
design 
10-fCV 
(outer) 
9-fCV 
(inner) 
10-fCV 
(outer) 
9-fCV 
(inner) 
10-fCV 
(outer) 
9-fCV 
(inner) 
Type of MC-
SVM 
Classification 
(RBF with 
grid search) 
DAGSVM, 
WW 
CS 
OVO, OVR, 
DAGSVM, CS 
Feature 
selection 
KW, S2N 
OVR, 
S2N OVO, 
BW 
KW, S2N 
OVR, 
S2N OVO, 
BW 
Gain Ratio 
fromWEKA 
Complexity 
192011 
models 
144011 
models 
192011 
models 
Best Model 
Chracteristics 
74.1% accuracy 
WW 
C=10,7=0.01 
30 genes by Anova 
(KW) 
86.5% accuracy 
CS 
C= l,y=0.1 
30 genes by Anova 
(KW) 
89.7% accuracy 
OVO 
C=10. y=0.1 
Table 12: The classification performance and the best classifiers using nested cross validation 
in GEMS. We used 06 ->05 approach for binary class prediction (LT, NLT+Ctr). 
From the above initial studies we observed that the 06 ->05 approach performed 
better over combined (05+06) dataset and also binary class prediction gives better accuracy 
than the multi class prediction either three class (NT, NLT and Ctr) or chemical compound 
prediction. But nested cross validation using only SVM algorithms hinders our study using 
other types of algorithms. To avoid this, we used stratified cross validation by the 
recommendation of MAQC. 
But after MAQC 7th face-to-face meeting in May 2007, analysis groups and RBWG 
(statisticians) recommended to use a generic work flow for all the datasets without much 
variation in the data analysis plan. They recommended in this meeting to submit a specific 
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single data analysis plan (DAP) (Appendix D) from each analysis group to the RBWG 
approval. This is because; the main objective of this project is to standardize a better work 
flow for predicting clinical outcomes and its reproducibility consistently with future datasets. 
So, the statisticians recommended only one data analysis plan from one group irrespective of 
dataset studying. This makes the work flow independent of the dataset being studied and has 
a chance to study the parameters affecting the classification performance. 
Generic DAP from USM Group 
We proposed our single generic data analysis plan (DAP) (Appendix D) for all the six 
datasets for biostatistics (RBWG) group approval. The main features of our data analysis 
plan are, (i) it includes fold change combined p-value as dimensionality reduction and gain 
ratio as feature selection algorithm, (ii) batch effect correction on the two datasets (iii) 
Feature selection algorithm is implemented inside the cross validation (called stratified cross 
validation), (iv) We proposed to use SMO (linear), LibSVM (linear and RBF kernels), NB, 
and Voted Perceptron classification algorithms on all the endpoints to generate candidate 
("best" models) models, (v) MCC as the primary performance metric used to select candidate 
models due to highly imbalanced class datasets. 
The schematic diagram of our final work flow is shown in the figure (Figure 25). 
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Figure 25: The schematic diagram of the data analysis plan we studied 
Results for final candidate classifiers for each end point 
We selected the candidate or best model for each end point based on the MCC 
performance from the models generated by 5-fold CV with 10 iterations and with 5 
classification algorithms, so totally 250 models for each subset of gene lists generated by 
gain ratio algorithm. Also reported the popular performance metrics accuracy, sensitivity, 
specificity, AUC (area under ROC curve), RMSE along with MCC values for each model 
generated. Standard deviations are calculated for each performance metric from the models 
generated by the 10 iterations. We reported only the top five models for each endpoint along 
with the standard deviation values (Table 13-25). The first one among those five is our 
candidate model (best model) for that end point. 
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Among this 13 candidate models for 13 end points proposed by USM group, our 
candidate models chosen best for five end points based on the best MCC performance and 
better analysis plan accepting most of the RBWG recommendations. Here, I am providing 
the exact response sent by Campbell Gregory (FDA) with ratings and comments given by the 
RBWG. 
Recommendations 
"The 13 groups that reported all 13 endpoints and submitted a DAP are: 
CAS, CBC, Cornell, FBK, GeneGo, GHI, GSK, NCTR, SAI, Tsinghua, UIUC, USM, ZJU 
It is surprising SAS and NWU did not submit a DAP - presumably they did their analysis 
correctly, but it is unfair to assume so without reading the plan. Of these 13 groups, the 
following 7 appear to have the analysis done right, with the caveat that the more models the 
group chose from, the higher the scores are likely to be, representing greater overfitting. The 
two groups for which this is the largest problem are likely to be NCTR for the sheer number 
of models, and SAI with its very high standard deviations for model quality measures. CBC 
and Cornell also have an uncomfortably large number of models for my liking. 
CBC, Cornell, GHI, NCTR, SAI, USM, and ZJU 
Three additional groups (GSK, Tsinghua, and UIUC) could be included in this list if their 
write-ups provided better clarity that they were not somehow snooping/overfitting the data. 
SAS and NWU could also be considered if they submitted a write-up. 
104 
Based on the small chance of over-fitting, if I had to bet money on which models would hold 
up out of sample and be of high quality, I would select from only the following groups (and 
still look carefully under the hood): 
GHI, USM.andZJU 
Taking these three groups and ranking models by MCC, and choosing the top model by MCC 
gives the following selections I would make for the 13 endpoints, pending verification of the 
methodologies of the top 3 groups. 
A:ZJU 
B:GHI 
C:ZJU 
D:USM 
E:USM 
F:USM 
G:ZJU 
H:GHI 
I:ZJU 
J:ZJU 
K:USM 
L:USM 
M:GHI 
For all three groups, batch effect correction was not really addressed. Hence we need to think 
carefully about potentially rerunning these methodologies on batch effect corrected data for 
those studies where the validation set comes from a different array type or there is an 
expectation of large batch differences between training and validation sets." 
From comments and observations especially on the batch effect made by RBWG 
came from our mistake in filling the batch effect column in the analysis plan. I mentioned 
105 
about the batch effect correction method we applied in the summary of DAP, was not 
observed by the reviewers. Then we intimated about this mistake and corrected. 
Discussion 
This dissertation is about how to effectively apply data mining technologies to 
biological and clinical expression data. Some problems arising from gene expression 
profilings like batch effect are studied in depth using data mining techniques of feature 
generation, selection and integration with classification algorithms. Also this analysis effort 
in conjunction with MAQC consortium helps to facilitate a standard work flow for predicting 
better and reproducible classifiers using gene expression data. 
Initially, we participated in array outlier identification analysis with other members to 
identify a consensus array outliers. The purpose of this QC assessment exercise is to reach 
consensus on a subset of arrays that should be considered with reasonable confidence as 
outliers due to array quality concerns and also clear outliers would impact the performance of 
classifiers significantly. Our outlier identification using dChip and box-plot distribution 
performed well based on the meta-analysis. 
Our observations in the preprocessing stages indicated that the strong batch noise 
introduced at the level of array making could affect the performance of classifiers 
significantly. To overcome this difficulty we applied two batch adjusting algorithms in this 
study. In our compare and contrast studies of these batch adjustment algorithms, (Combat 
and Batchmatch) we observed that both performed similarly in correcting the batch but 
Batchmatch has several advantages over Combat in terms of class label information leakage 
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and batch reference. These features could help more when we are analyzing the performance 
of classifiers with external validation or blind datasets. 
In order to identify genes associated with disease phenotype classification or patient 
survival prediction from gene expression data, we compared and analyzed the performance 
of five feature selection algorithms. Our observations from these studies, indicated that 
gainratio algorithm performs better and consistent over the other algorithms studied. This 
makes to take gainratio as our feature evaluation algorithm for further classification studies 
with other datasets. 
When it comes to performance metric to choose the best classifiers, MAQC 
recommends of using Matthews' correlation coefficient (MCC) as primary performance 
metric especially when we are dealing with highly unbalanced class datasets. Because of, 
MCC takes all four elements of the two class confusion matrix into consideration avoids you 
the bias, our observation and studies strengthen the above recommendation that, MCC gives 
unbiased performance results over accuracy in some endpoints (K and M), where class 
imbalance is more. 
In the aspect of classification algorithms, no single algorithm is absolutely superior to 
all others, though SVM achieved fairly good results in most endpoints. Naive bayes 
algorithm also performed well in some endpoints. In overall, from the total 60 models we 
reported (5 top models for 13 end points) SVM and SMO (a variant of SVM) dominates 
mostly, also the linear kernel performed well over RBF in our binary classifications. 
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Future work 
Currently, our proposed generic data analysis work flow for this classification 
purpose would help along with other groups analysis to come to a conclusion about the 
standardize methodology. But the candidate models for all the endpoints generated from 
these training datasets from all groups should validate with the external blind datasets to 
know how well they perform with unknown data. Presently, the consortium is working hard 
on providing the blind datasets to analysis groups, most probably by the end of this month. 
As part of this study and discussions with in the consortium, several groups proposed 
the manuscript ideas to publish the work done by the analysis groups by meta analysis. 
Among one of them, Dr. Deng proposed meta-analysis of gene features used in the candidate 
models across the groups in all endpoints. This study facilitates finding the consensus gene 
lists using the genes the groups used for their candidate model for a particular end point. 
After finding the consensus gene lists, ranking them based on the number of occurrences in 
the candidate models. Generating the new classifiers and comparing the performance 
validation with already known candidate models using the top consensus gene list could be 
an interesting work. We are currently working on these analysis after getting the summarized 
results from other groups. 
We are also working the effect of batch on the classification and how could we 
quantify the batch noise along with other groups. 
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APPENDIX - D: USM Data Analysis Plan (DAP) 
Part A: Data Analysis Team 
University of Southern Mississippi 
Venkata Thodima (venkata.thodima@usm.edu, 601-266-4353) 
Primary Contact - Dr. Youping Deng (youping.deng@usm.edu, 601-266-6678) 
Part B: DAP Summary 
USM will analyze six datasets with four different machine learning algorithms (LibSVM, SMO, Naieve Bayes and 
Voted perceptron), and select one best model for each dataset as final model. We omitted the outliers from analysis 
specified in each dataset by the QC working groups. Batch effect will be treated in the Hamner and Iconix datasets 
based on parametric and nonparametric Empirical Bayes frameworks available in one of R function (Combat). We 
will use fold level and P-value (0.05) filter for dimensionality reduction and further ranking of features will be based 
on Gainratio feature selection algorithm. 
Part C: Brief Data Description - see Appendix A for more details 
Dataset Type 
Dataset Source 
Disease or 
Toxicity (s) 
Primary 
Prediction 
Endpoint (s) 
Microarray 
Platform 
Channel(s) 
Training 
Samples after 
QC 
Sample QC 
Batch effect 
Other 
Endpoint (s) 
Toxicogenomic 
Hamner 
Lung Cancer 
Predict NTP 
long term 
assay lung 
carcinogenicity 
from 3 month 
exposure 
Affy 430.2 
(Mouse) 
1 
70 
ByQC 
subgroup (1) 
Strong (2), 
Batch effect 
corrected 
Iconix-EPA 
Liver 
Toxicity 
Predict NTP 
long term 
hepatotoxicity 
from 5 to 7 
day exposure 
Codelink-
RU1 (Rat) 
1 
216 
ByQC 
subgroup 
Strong (3), 
Batch effect 
corrected 
NIEHS 
Rat Liver 
Toxicity 
Liver 
necrosis 
Affy-
RG230 2 
(Rat) 
1 
214 
ByQC 
subgroup 
Slight 
and 
equivocal 
(4) 
Clinical 
MDACC 
Breast 
Cancer 
Treatment 
Outcome & 
Prognosis 
Affy 
HGJJ133A 
(human) 
1 
130 
ByQC 
subgroup 
Slight and 
equivocal 
UAMS 
Multiple 
Myeloma 
Subtype & 
Treatment 
Outcome: a) even 
free survival 
(EFS); b) overall 
survival (OS); 
Affy 
HG_U133_plus_2 
(Human) 
1 
340 
By QC subgroup 
Slight and 
equivocal 
U Cologne 
Neuroblastoma 
Subtypes and 
three year: a) 
even free 
survival (EFS) 
b) overall 
survival (OS); 
Agilent-NB-
10707 (Human 
Custom) 
2 (Dye Swap) 
246 
ByQC 
subgroup 
Slight and 
equivocal 
See Appendix A 
We will think about the other endpoints after some more clarity about UAMS and Cologne 
datasets, seems the CWG will update about this soon according to the teleconference. 
Part D: Data Pre-Processing 
Raw data 
preprocessing 
Transforms 
Summarization 
(for probe-
level data) 
Normalization 
None None None None None Background 
substraction 
(fg-mean BG) 
Baseline transformation and Log2 
MAS5 
Median scale 
1000 (provided 
byMAQC) 
MAS5 MAS5 MAS5 NA 
Agilent Mean 
scale 
normalization 
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Part E.l: Classification Method (s) 
(Part F. is intended to be a simplified matrix of the modeling algorithm (s) that will be used on each dataset. 
However, note that the final model will have to be based on one algorithm of the data analysis team's choosing. 
Chronology 
and parameter 
space 
reduction 
Classification 
Method 
Classification 
Method(s) 
Eliminated 
Chronology of dataset analysis: In the anticipation thai there may be some learning and reduction 
of the modeling process across each dataset considered, an indication of the chronology of 
analysis may be appropriate. For example, if after the first two datasets considered it is 
determined that one class of models is either too computationally expensive or appears to be 
leading to poor results, the class of models may be dropped for subsequent datasets. Alternatively, 
model parameter spaces (e.g., number of genes) may be reduced. 
LibSVM 
5 
SMOS Naieve Bayes 1 Voted perceptron 8 
Wc eliminated KNN, J48 and Bagging algorithms because of poor performance in our exploratory 
investigation. 
Fart £.2: Molecular Feature Filtering (i.e., features removed) and Selection 
(Note that some AGs might imbed or nest feature selection within the modeling algorithm such as by a Monte Carlo. 
genetic algorithm or within cross validation, etc.. or by some combination of these. Other approaches could be based 
on biological insights or relevance, such as disease-related genes or pathways - there are endless possibilities) 
A Priori 
Feature 
Reduction 
Filtering 
A Priori 
Feature Pool 
Selection 
Features 
removed based 
on biological 
considerations 
Features 
selection 
through cross 
validation 
Filtering based on low signals and flags (P/M absolute calls) 
Further reduction in number of genes based on the fold change (2) but in some end points less than 
2 and P-value (<0.05) 
None 
Gain ratio 11 
The above feature selection method with 5f cross validation 
Part E.3: Non-Molecular Feature Selection (i.e., features added other than from the microarray data) 
Features 
derived from 
clinical data 
Features 
derived from 
disease-
associated 
genes, proteins 
and/or 
pathways 
Features 
derived from 
other in vitro 
or in vivo data 
sources 
NO 
NO 
NO 
Part £.4: Internal Validation (e.g., training and internal test set split and or Cross-validation (CV) 
Training set 
samples 
Internal test set 
set-aside 
115 
samples 
OR by Cross 
validation 
Level of 
Cross-
validation 
5fCV 5fCV 5fCV 5fCV 5fCV 5fCV 
Stratified CV with 10 iterations 
Part E.5: Model Tuning Criteria by Dataset 
Single 
performance 
tuning criteria 
Or, Dataset 
dependent 
performance 
MCC, Accuracy, sensitivity, specificity, RMSE and AUC are reported with 
std.dev. 
But model selection based on MCC 
TBD TBD TBD TBD TBD TBD 
Part E.6: Modeling Procedure and Model Tuning by Method 
Classification 
procedure flow 
and logic 
Method 
Parameter(s) 
Number of 
Features 
Level of cross-
validation 
Process 
FOUR different methods will be applied to each dataset to enable systematic comparison: 
LibSVM (linear and 
RBF) 
SMO (linear) Naieve Bayes Voted Perceptron 
Stratified 5f CV with 10 iterations, c=10 and gamma=0.01 
See figure 1 
I 
(Ap 
Number 
samples from 
original data 
source held out 
for blinded, 
confirmatory 
test 
Prospective 
dataset number 
1 
Prospective 
dataset number 
2 
Endpoints to 
be predicted 
Procedure 
Batch effect 
treatment 
Prediction 
performance 
criteria 
40 
LTandNLT 
'art F: Confirmatory Blinded Test Procedure 
nendix A contains information germane to this part) 
201 
Liver 
cancer and 
non-liver 
cancer 
204 
Overall 
necrosis 
score 
About 100 
Tr. 
response 
andER 
214 
TBD 
200 to 300 
TBD 
Using the best model from the corresponding dataset 
Yes 
TBD 
No 
TBD 
No 
TBD 
No 
TBD 
No 
TBD 
No 
TBD 
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Footnotes: 
1 - Used array data distributed after QC by MAQC QC subgroups, whereby suspect arrays were 
removed by a consensus method. 
2 - Exploratory analysis revealed a highly relevant batch effect that dictated setting aside a portion of 
the training samples as a testing set. Specifically, training samples were divided between arrays from a 
2005 batch and a 2006, with 2006 arrays used for training, and 2005 arrays used for external testing. 
3 - The data exhibited a strong time temporal dependency, with distinct separation into three batches 
4 - Exploratory analyses indicated that the batch effect was too small to affect modeling and 
predictions (results not shown) 
5 - LibSVM: Library of SVM developed by Chung Chang and Jen Lin, both Linear and RBF kernel 
type with c=10 and gamma = 0.01 
6 - SVM-linear: This method involves the construction of binary SVM classifiers for all pairs of 
classes; 
7 - Class for a Naive Bayes classifier using estimator classes. Numeric estimator precision values are 
chosen based on analysis of the training data. 
8 - A variant of perceptron algorithm. Implementation of the voted perceptron algorithm by Freund and 
Schapire. Globally replaces all missing values, and transforms nominal attributes into binary ones. 
11 - Evaluates the worth of an attribute by measuring the gain ratio with respect to the class. Ranks 
attributes by their individual evaluations. 
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APPENDIX - E: Summary of the candidate models for 13 endpoints and the gene lists 
used for each model 
End point A: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
1 
USM Hamner A 1 
MAS5 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
20 in final model 
LibSVM-RBF 
Weka, R 
1426280_at 
1419476_at 
145025 l_a_at 
1418668_at 
1437580_s_at 
1423410_at 
1435647_at 
1420683_at 
1456823_at 
1440314_at 
1449555_a_at 
1455048_at 
1420723_at 
142253 l_at 
1425767_a_at 
1452804_at 
1455760_at 
1460012_at 
1435323_a_at 
1420377 at 
Coefficients 
(If applicable) 
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End point B: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
6 
USM Iconix B 1 
MAS5 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
30 in final model 
LibSVM-LIN 
Weka, R 
NM_013200_Probel 
NM_019157_Probel 
AI715955_Probel 
BF387347_Probel 
X92495_Probel 
AW914013_Probel 
AF031879_Probel 
AW914913_Probel 
U37058_Probel 
BE108246_Probel 
M26199_Probel 
AW525290_Probel 
AW524548_Probel 
AW535381_Probel 
X61925_Probel 
AW533257_Probel 
BF286131_Probel 
AW529672_Probel 
AW525189_Probel 
BE109912__Probel 
BF404878_Probel 
BF401593_Probel 
D86345_Probel 
BF405177_Probel 
D12498_Probel 
BE118122_Probel 
AW531250_Probel 
AW525089_Probel 
AF024622_Probel 
All 13076 Probel 
Coefficients 
(If applicable) 
End point C: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
11 
USM NIEHS C 1 
MAS5 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
20 in final model 
LibSVM-RBF 
Weka, R 
1370902_at 
1370832_at 
1371785_at 
1371400_at 
1371412_a_at 
1370355_at 
1370080_at 
1370150_a_at 
1370725_a_at 
1370583_s_at 
1370670_at 
1374610_at 
137459 l_at 
1375170_at 
1374625_at 
1374765_at 
1373778_at 
1372510_at 
1372729_at 
1374529 at 
Coefficients 
(If applicable) 
End point D: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and 
coefficients in model 
Description 
16 
USM BR D 1 
MAS5 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
50 in final model 
NB 
Weka,R 
208712 at 212960 at 
218236 s at 201030 x at 
204623 at 218211 s at 
208711 s at 203108 at 
201508 at 215726 s at 
205225_at 213032_at 
216092 s at 209290 s at 
215867 x at 213564 x at 
204667 at 217762 s at 
212190 at 209773 s at 
218807 at 203476 at 
212956 at 204822 at 
212444 at 209459 s at 
208103 s at 211864 s at 
214164 x at 207843 x at 
213134 x at 218806 s at 
209289 at 205548 s at 
204825 at 217838 s at 
210735 s at 210652 s at 
202088_at 212195_at 
205066 s at 208682 s at 
205347 s at 
203963_at 
202870 s at 
203789 s at 
209366 x at 
209173_at 
209604 s at 
202089_s_at 
Coefficients 
(If applicable) 
End point E: 
Steps Description Coefficients (If applicable) 
Serial # 21 
Model ID USM BR E 1 
Normalization MAS5 
Pre-Filtering of genes FoldChange+P-value 
Feature Selection Step 1 Gain Ratio with Cross validation approach 
Number of Features 30 in final model 
Classifier SMO 
Software Packages used Weka, R 
Gene list and coefficients 
in model 
205225_at 
209602_s_at 
203963_at 
214164_x_at 
215867_x_at 
217838_s_at 
212960_at 
214440_at 
204623_at 
209173_at 
209696_at 
218195_at 
212956_at 
209604_s_at 
214404_x_at 
205066_s_at 
221765_at 
202089_s_at 
212771_at 
210735_s_at 
221016_s_at 
203749_s_at 
212148_at 
212190_at 
218807_at 
212209_at 
212492_s_at 
201508_at 
220192_x_at 
209289 at 
End point F: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
26 
USM MM F 1 
RMA 
FoldChange + P-value 
Gain Ratio with Cross validation approach 
40 in final model 
NB 
Weka, R 
236558_at 215982_s_at 
1555878_at 218701_at 
1554899_s_at 218984_at 
209945_s_at 204204_at 
225917_at 228955_at 
223625_at 224523_s_at 
202416_at 202107_s_at 
213194_at 212022_s_at 
201602_s_at 211973_at 
211908_x_at 212021_s_at 
205529_s_at 211944_at 
216956_s_at 211963_s_at 
204159_at 211979_at 
211641_x_at 211990_at 
242104_at 
22775 l_at 
218859_s_at 
218187_s_at 
211650_x_at 
211576_s_at 
209098_s_at 
1569454_a_at 
201614_s_at 
228324_at 
213320_at 
201558 at 
Coefficients 
(If applicable) 
End point G; 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
31 
USM MM G 1 
RMA 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
24 in final model 
LibSVM-LIN 
Weka,R 
217934_x_at 
223506_at 
209206_at 
210205__at 
210178_x_at 
210244_at 
210220_at 
210231_x_at 
210057_at 
210052_s_at 
200602_at 
204379_s_at 
209053_s_at 
209374_s_at 
211645_x_at 
214768_x_at 
214777_at 
215176_x_at 
216207_x_at 
216401_x_at 
216576_x_at 
217378_x_at 
222777_s_at 
234764 x at 
Coefficients 
(If applicable) 
End point H: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
36 
USM MM H 1 
RMA 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
21 in final model 
LibSVM-RBF 
Weka, R 
201909_at 
204409_s_at 
204410_at 
205000_at 
20500 l_s_at 
206624_at 
206700_s_at 
20903 l_at 
214131_at 
214218_s_at 
221728_x_at 
223645_s_at 
223646_s_at 
224588_at 
224589_at 
224590_at 
22767 l_at 
228492_at 
230760_at 
232618__at 
236694 at 
Coefficients 
(If applicable) 
End point I: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
41 
USM MM I 1 
RMA 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
40 in final model 
LibSVM-LIN 
Weka,R 
211302_s_at 212063_at 
211026_s_at 212076_at 
211084_x_at 212221_x_at 
211919_s_at 212223_at 
211962_s_at 212209_at 
211473_s_at 212220_at 
211505_s_at 209318_x_at 
210568_s_at 209279_s_at 
210756_s_at 209309_at 
210479_s_at 209498_at 
210538_s_at 209512_at 
210807_s_at 209427_at 
210986_s_at 209456_s_at 
210785_s_at 208657_s_at 
210788_s_at 208890_s_at 
212338_at 208373_s_at 
212233_at 
212334_at 
212415_at 
212568_s_at 
212392_s_at 
212409_s_at 
212085_at 
212090 at 
Coefficients 
(If applicable) 
End point J: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
46 
USM NB J 1 
MAS5 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
20 in final model 
LibSVM-LIN 
Weka, R 
A23P74349 
A_23_P401 
A_23_P44155 
A_23_P145529 
A32P159234 
A_32_P151800 
A_32_P143245 
AJ2P44831 
A_32_P77989 
A_23_P335329 
A_24_P96780 
A24P57047 
A_23_P10385 
A_23_P51085 
A_23_P17575 
A_23_P163306 
Hs23960.1 
Hsl43769.1 
A_23_P102331 
A_23_P386 
Coefficients 
(If applicable) 
End point K: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
51 
USM NB K 1 
MAS5 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
30 in final model 
NB 
Weka,R 
A23JP149668 
A32JM981 
A_23_P501831 
A_32_P47538 
A_32_P190303 
A32P4985 
A_32_P134756 
A_23_P48669 
A_23_P396765 
A_24_P88696 
A_24_P297539 
A23P133123 
Hs75426.3 
A_23_P323751 
A_23_P2543 
A_23_P155765 
Hs87507.1 
A_23_P125680 
A_23_P96325 
A_23_P254733 
A_23_P138507 
A_23_P100711 
A_24_P98021 
A_32_P171043 
A_23_P65757 
A_24_P902509 
A 23_P23303 
A23P157027 
A_23_P115872 
A 32 P30874 
Coefficients 
(If applicable) 
End point L: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
63 
USM NB L 1 
MAS5 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
20 in final model 
SMO 
Weka, R 
A_23_P259314 
A_24_P500584 
AJ23P137238 
Hs456200.1 
A_23_P309224 
A_23_P429950 
A_32_P212471 
A_23_P315345 
A23P125519 
A_23_P162766 
A_24_P186030 
A_32_P183001 
A_23_P156970 
A_24_P134653 
A_24_P237389 
A_23_P146997 
A_23_P217409 
A_23_P148629 
A_23_P93009 
A 23 P136870 
Coefficients 
(If applicable) 
End point M: 
Steps 
Serial # 
Model ID 
Normalization 
Pre-Filtering of genes 
Feature Selection Step 1 
Number of Features 
Classifier 
Software Packages used 
Gene list and coefficients 
in model 
Description 
68 
USM NB M 1 
MAS5 
FoldChange+P-value 
Gain Ratio with Cross validation approach 
20 in final model 
NB 
Weka, R 
Hs32976.1 
A_32_P83570 
A_23_P251151 
Hs301404.34 
A_23_P35277 
A_24_P37540 
A_23_P316012 
A23P151895 
Hs284281.1 
A_24_P184931 
A_24_P260443 
A_32_P97169 
A_23_P214897 
A_24_P63290 
A_24_P389251 
A_32_P196837 
A_23_P45536 
A_24_P372833 
A_23_P132718 
A 23 P257649 
Coefficients 
(If applicable) 
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